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Abstract 
 
 Molybdenum-dependent xanthine oxidoreducatases (XOR) are a well-known 
family of enzymes, which oxidise purines, imines and aldehydes in cellular metabolism. 
Despite many studies relating to drug metabolism, application to chemical synthesis has 
only recently begun to be explored. 
 Herein we report the first use of XORs in the cascade synthesis of lactams from 
cyclic amines by the combination of the mutant monoamine oxidase (MAO) MAO-N 
D9 and XOR (E.coli XDH & R. capsulatus XDH E232V). A number of single step 
imine oxidations were also performed in excellent conversions with the methodology 
comparing well to current chemical oxidation methods. The reactions were performed 
in water at ambient temperature and pH using oxygen as the terminal oxidant with the 
only by-product being H2O2.  
A solid-phase colorimetric assay has been developed to detect aldehyde oxidase 
activity from membrane-bound bacterial colonies of TP1000 x PaoABC using a coupled 
peroxidase system. The screen was used to assay a library of mutants generated at the 
Moco-containing sub unit of PaoABC with phenylacetaldehyde used as a model 
substrate. This resulted in the discovery of an improved mutant L443Q, which exhibited 
improved solid-phase activity in addition to improved kinetics. 
A saturation mutagenesis approach has also been employed on Ec PaoABC at 
analogous positions responsible for substrate binding in Rc XDH to search for a novel 
“imine oxidase”. An interesting variant L246G was isolated with a switch in substrate 
specificity toward 3,4-dihydroisoquinoline.  
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HCN Hydrogen cyanide 
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NADP Nicotinamide adenine dinucleotide phosphate 
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P2O Pyranose-2-oxidase 
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PCR Polymerase chain reaction 
PEF Polyethylene furanoate 
PET Polyethylene terephthalate 
RP-HPLC  Reverse phase high pressure liquid chromatography 
RT-PCR Reverse transcriptase-coupled PCR 
TA Transaminase 
Taq Thermus aquatacus 
TEMPO (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl  
TFA Trifluoroacetic acid 
THBC Tetrahydro-β-carboline 
THF Tertahydrofuran 
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UMP Uridine monophosphate 
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Chapter 1 
1. Introduction 
1.1. Green chemistry 
 
Green chemistry is a broadly reaching discipline encompassing synthesis, 
chemocatalysis, biocatalysis and chemical engineering.[1-5] Reducing the impact of non-
renewable and hazardous materials on human health and the environment emerged as an 
independent branch of chemistry over two decades ago.[6] In 1990 the US pollution 
prevention act was passed, which encouraged companies to reduce the level of 
pollutants produced through cost-effective modifications to chemical processes and 
handling of raw materials.[7] The journal Green Chemistry first published in 1999 by the 
Royal Society of Chemistry has become a hub for all aspects of sustainable chemistry 
and new methods in chemical engineering. Green chemistry’s aim was more clearly 
defined following the publication “12 principles of green chemistry” first developed by 
Anastas and Warner.[8] 
 
1.1.1. The twelve principles of green chemistry 
 
The principles are intended as a guide in reducing the environmental impact of 
chemical production and are summarised as follows. 
 
1) Prevention of waste preferred over treatment of waste 
 
2) Methods of synthesis should be atom efficient 
 
3) Synthetic products should not possess human/environmental toxicity 
 
4) Products should retain efficacy while reducing toxicity 
 
5) Solvents and other auxiliaries should be unnecessary where possible 
 
6) Reduction of energy requirements and use of ambient conditions 
 
7) Use of renewable feedstocks  
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8) Reducing derivatives (i.e. protection/deprotection) 
 
9) Moving toward catalytic reagents from stoichiometric  
 
10) Design of biodegradable products 
 
11) Analytical methods for real time hazard/pollutant prevention 
 
12) Use of safer reagents, which are benign in the event of an accidental spill 
 
E factor (mass waste/mass product) and atom economy (atoms of product/atoms 
of all reagents) are two concepts devised by Roger Sheldon in the early 1990’s and give 
a measurement of the environmental footprint for a given chemical process.[2] A decade 
prior, Sheldon had been alerted to the problem of waste after observing the closure of a 
plant producing phloroglucinol. The process that made the fine chemical on a moderate 
scale was producing 40 kg of waste for every 1 kg of product, the cost of disposal of 
which was negating any profit. After surveying other processes, it was clear that large 
amounts of waste were abundant in the fine chemical and pharmaceutical industries. In 
order to reduce the amount of waste being produced a paradigm shift from yield 
optimisation to also including environmental considerations in process design would be 
necessary.  
 
1.1.2. Alternative energy & solvent 
 
In addition to reducing the use of unsustainable and hazardous materials, an 
emphasis in reducing energy and solvent requirements is a key factor in greening 
synthesis. This has resulted in several approaches of using benign media/solvent free 
systems with alternative energy sources to drive reactions forward.  
 
Mechanochemical mixing methods have been used to facilitate several solvent 
free reaction types including Biginelli,[9] Reformatsky,[10] Luche[10] and Sonogashira.[11] 
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Scheme 1 Stereoselective reduction of a chiral diketone[12] 
 
For example a diastereoselective reduction by grinding the reaction using a pestle 
and mortar furnished the chiral alcohol 2 in excellent optical purity, albeit in modest 
yield (Scheme 1).[12] This example of a solvent free approach is remarkable in that it is 
fully regio and diastereoselective, while not using harsh conditions.  
Ultrasound has been utilised as an alternative form of energy input in reactions 
and has seen use in organic synthesis due to its selectivity in reactions, which offer 
results from use under ambient conditions. 
 
 
Scheme 2 Ultrasonic Heck coupling in ionic liquids[13] 
 
Srinivasan et al. were able to use ultrasonication with ionic liquids to perform 
Heck couplings on a range aryl iodides to give exclusively E products in good to 
excellent yields (Scheme 2).[13] Heck reactions usually require long reaction times 
under reflux in polar solvents such as DMF. Ionic liquids themselves can also be 
generated using ultrasonication. Varma et al. synthesised 1,3-dialkylimidazolium 
compounds at room temperature using neat reagents and sonication, ordinarily these 
compounds require an excess of alkyl halide and an organic solvent.[14]  
 
Microwaves as an alternate source of energy input have the advantages of uniform 
heat transfer, rapid initial heating and increased reaction kinetics. This has resulted in a 
solvent free alternative method of heating that is comparable or better than conventional 
heating. For example polyamides were prepared through microwave irradiation for 30 
seconds whereas conventional heating took 1 minute.[15,16] Microwave irradiation 
O
O
NaBH4
O
OH
grinding 54%
1 2
54 %
100 % e.e.
I
R1 R
2 Pd(OAc)2 (2 mol %) NaOAc
[bbim]+ Br- [bbim]+ BF4-
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R2
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 4 
delivered diazepines and pyrazoles in a facile manner through condensation of 
hydrazines/diamines with 1,3-diketones in the absence of both solvent and catalyst 
(Scheme 3).[17] 
 
 
Scheme 3 Solvent and catalyst free synthesis of pyroles and diazepines[17] 
 
Other notable transformations in solvent free conditions include synthesis of 
hydrazones,[18] 1,3-thiazoles[19] and ionic liquids.[20] Using basic water as solvent, 
efficient synthesis of N-heterocycles was carried out by microwave-facilitated double 
alkylation of primary amines[21] and hydrazines (Scheme 4).[22] 
 
 
Scheme 4 Microwave irradiated synthesis of N-heterocycles in aqueous media[21,22] 
The selective absorption of microwaves by polar reagents, which are normally 
insoluble in aqueous media is believed to act as a surrogate phase transfer catalyst. 
Polyethylene glycol is a benign and cheap reaction solvent, which has been used 
successfully in microwave promoted Suzuki cross-coupling reactions to deliver simple 
bi-aryls such as 17.[23] 
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Scheme 5 MW facilitated Suzuki reaction in polyethylene glycol[23] 
 
Nanomaterials have rapidly emerged with wide reaching applications in medicine, 
electronics, communications, and materials science.[24] Conventional methods of 
metallic nanoparticle preparation involve strong reducing agents and/or capping agents 
(i.e. polyvinyl pyrrolidone) in addition to a large amount of organic halide as solvent. 
Natural oxidants like polyphenols found in tea can function as reductants and have been 
used in the production of gold and silver nanoparticles and this presents an attractive 
green alternative to conventional synthesis.[25]  
 
A limitation of nanoparticles is that they are prone to aggregation, which 
drastically reduces activity due to decreased effective surface area. Stabilising agents 
are therefore required to retain activity and extend shelf life but significantly contribute 
to waste streams. Developments in green stabilising agents have meant that 
biodegradable polymers and biocatalyst stabilisers are viable options.[26] 
 
1.1.3. Biorenewable materials 
 
The ability to effectively utilise renewable resources in fuel and materials 
production will be a key factor in mitigating the increasing danger posed by climate 
change.[27] Biomass is a sustainable resource comprised chiefly of lignocellulose and 
triglycerides that has seen increased adoption from industry in the last decade with 
emerging dedicated biorefineries.[28] In addition to biofuels and chemicals, refineries 
providing greener materials such as bio-derived plastics can lower costs and reduce 
carbon footprint.[29] 
 
 
B
HO
HO
Br
PEG-400, 81 %
PdCl2, KF, MW
15 16 17
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Scheme 6 Primary conversion options for lignocellulose[3] 
 
Lignocellulose from plant biomass is comprised of polymeric sugars and aromatic 
lignin. It is extremely abundant in nature and being inedible, its use in manufacturing 
doesn’t compete with other materials derived from foodcrops such as starch and 
vegetable oil. Processing lignocellulose is more challenging than crop based feedstocks 
and involves depolymerisation and then deoxygenation.[30] The first step can be carried 
out by thermochemical treatment (pyrolysis/gasification) or hydrolysis (Scheme 6). 
This is usually carried out in water although ionic liquids can dissolve lignocellulose[31] 
and, with water, has potential for chemocatalytic[32] and biocatalytic hydrolysis.[33]  
 
Lignocellulose Pyrolysis oil
H2
zeolite
Lower olefins
pyrolysisgasification
Syn gas
MeOH
Lower olefins,
BTX
zeolite Lignin + Cellulose + Waste protein
pretreatment
hydrolysis
C5 + C6
sugars
fermentation alcohols,
diols, acids
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Scheme 7 Paths to bio-derived PET[3] 
 
Polyethylene terephthalate (PET) is an industrial polymer utilised ubiquitously in 
plastic bottles and accounts for a significant percentage of plastics produced globally 
(>50 million tonnes). The components of PET are terephthalic acid and ethylene glycol, 
which themselves are produced from ethylene and crude oil-derived xylene. 
Development of biobased counterparts from hexose and pentose have led to partial (~30 
%) and fully plant based PET bottles. Three routes to bio-p-xylene are depicted above 
(Scheme 7). Route 1 (R1) involves the addition of bioethylene to biomass-derived 2,5-
dimethylfuran in a zeolite catalysed Diels-Alder cyclisation with loss of water. [34,35] 
The second and third routes both involve industrial processes from Gevo[36] and Virent 
respectively. Gevo’s patented process involves fermentation of sugars to produce bio-
isobutanol 19, which then undergoes dehydration and metathesis to deliver the C8 
alkene 21. Dehydrocyclisation using a specific catalyst then yields p-xylene. The Virent 
process involves aqueous phase reforming (APR) and dehydrocyclisation to deliver a 
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mixture of benzene, toluene and various xylenes (BTX) from which p-xylene can be 
isolated.  
 
 
Scheme 8 Path to bio-polyethylene furanoate[37] 
 
Alternatively, a replacement bio-derived polymer, poly-ethylene furanoate (PEF) has 
been developed by Avantium (Scheme 8), where terephthalic acid is replaced by 
furandicarboxylic acid (FDCA), which is also obtained from hexose sugars through acid 
catalysed dehydration followed by oxidation.[37] FDCA is readily formed from the less 
stable intermediate hydroxymethyl furfural (HMF)[28] and is recognised as a key sugar-
based platform chemical by the US Department of Energy.[38] 
1.2. Enzyme biocatalysts 
 
Enzymes have been utilised in fermentation processes to produce alcohol and 
foodstuffs throughout history. The first reported synthetic use of enzymes occurred in 
1858 when Louis Pasteur isolated optically pure (-)-tartaric acid through selective 
consumption of the opposite enantiomer by Penicillium glaucum mould.[39] This is also 
considered the first example of an enzyme driven resolution. Later work by Eduard 
Buchner at the end of the 19th century demonstrated that biotransformations didn’t 
C5 + C6
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O
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require living cells by successfully fermenting sugar with yeast cell extract thereby 
identifying enzymes as independently acting units.[40] 
Owing to their chemo-, regio- and stereoselectivity, enzymes have become great 
assets available to a synthetic chemist for greening synthesis.[41] Biocatalysts operate 
optimally in aqueous media under ambient conditions at neutral pH, are biodegradable 
and safe. This results in catalysts that often preclude the use of organic solvent and 
harsh temperature/pressure. Many enzymes (i.e. lipases, proteases) are also functional in 
organic solvent. This has been exploited by industry where many processes utilise 
solvents for their ease of product extraction. Enzymes can also bypass conventional 
synthetic protection/deprotection strategies due to their chemoselectivity, which 
increases atom economy. 
 
1.2.1. Enzyme structure and function 
 
Enzymes are macromolecules consisting of a typically globular protein and may 
also possess one or multiple co-factors. Deconstruction reveals a distinct four-tier 
hierarchy of structure; primary, secondary, tertiary and quaternary (Figure 1).[42] 
Primary structure consists of a specific sequence of α-amino acids connected through 
strong peptide bonds in an order defined by the protein’s genetic code. The dual 
hydrogen donating and accepting character present in amides leads to H-bonding 
between neighbouring amino acids. This produces secondary structures, the most 
common of which are α-helixes and β-sheets.  
  
 
Figure 1 Protein structure starting from primary through quaternary[42] 
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A single peptide backbone containing secondary structures folds into a compact 
and stable tertiary structure. This is driven by the lower energy obtained by isolating 
alkyl and other non-polar hydrophobic residues internally. Conversely, polar 
hydrophilic residues are situated towards the surface of the protein to interact with 
water. Additional bonding interactions including; π-π stacking, Van der Waals forces, 
salt bridges and cysteine di-sulfide bridges contribute to give a globular 3D shape. 
Higher order quaternary structures arise as a result of these additional interactions 
occurring between separate ordered tertiary structures. 
Co-factors consist of inorganic ions and organic co-enzymes, which can be 
loosely or covalently bound and assist in the activity of an enzyme.[41] Tightly bound 
co-factors termed prosthetic groups function at the active site to facilitate reactions.  
 
 
Scheme 9 Interconversion of oxidised and reduced NAD(P)+ and FAD 
 
Metals such as iron, cobalt, molybdenum and copper are common inorganic 
prosthetic groups, while NAD(P)H and FADH are important for electron transport and 
metabolism (Scheme 9). Co-factors function by assisting in processes the enzyme 
cannot carry out alone such as metabolism and electron transfer. Co-enzymes are also 
not considered part of the main protein, as they are transient and frequently recycled. 
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1.2.2. Mechanisms of enzyme activity  
 
Enzymes function similarly to other catalysts in that they increase the rate without 
affecting the equilibrium of a given reaction. Enzymes in particular can increase the rate 
of a reaction by many orders of magnitude.[42] 
 
 
Scheme 10 UMP biosynthesis through OMP decarboxylase 
 
 Orotidine 5’-phosphate decarboxylase catalyses the biosynthesis of uridine 
monophosphate 32 (UMP) and is an extremely efficient catalyst with a rate 
enhancement of 1017 (Scheme 10). Other notable examples of rate enhancement include 
urease (1014) and phosphoglucomutase (1012).  
 
 
Figure 2 Single enzyme-substrate reaction where E = enzyme, S = substrate, ES = enzyme-
substrate complex and P = product 
 
A standard enzyme-catalysed reaction can be represented in a simplified manner 
as depicted above (Figure 2), where the formation of product from the enzyme-
substrate complex is assumed to be the rate-limiting step. 
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Figure 3 Michaelis-Menten rate equation and saturation curve[43] 
 
The Michaelis-Menten model is a simple and popular method of enzyme kinetics, 
relating reaction rate to substrate concentration for a single enzyme and substrate 
(Figure 3).[43] Key terms described by the rate equation are: initial rate V0, the maximal 
rate Vmax, initial substrate concentration [S] and the Michaelis constant Km. Additional 
parameters derived from this include the catalyst rate constant kcat and the enzyme 
specificity constant kcat/Km. These parameters can be experimentally measured and are 
often used to compare the activity between enzymes on a given substrate.  
Enzyme catalysis is accomplished through reducing the activation energy by 
either providing an alternate low-energy pathway or reducing the transition state energy, 
both of which enable the reaction to proceed faster  (Figure 4).[42]  
 
Figure 4 Reaction coordinate vs free energy (black = non-enzyme catalysed, blue = enzyme 
catalysed)[42] 
 
V0 =
Vmax [S]
Km + [S]
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Like other catalysts, enzymes remain unchanged after taking part in a chemical 
process. A distinguishing feature of biocatalysed reactions is that they take place in an 
enzymes active site; an internal compartment containing surface amino acid residues 
involved in chemical transformation and substrate binding. Here an enzyme-substrate 
complex is formed providing a lower energy pathway.  
Emil Fischer originally postulated the formation of such complexes to be 
completely complimentary in 1894.[44] It is now known that the lock and key hypothesis 
would actually result in a poor enzyme. This is because an enzyme that is completely 
complementary to a substrate would stabilise the ground state ES complex and be 
unable to overcome the energy required to reach the transition state (Figure 4).  
Instead, to overcome the issue of ΔG, Linus Pauling described a natural 
progression of Fischer’s theory where the reaction transition state was stabilised by the 
enzyme instead.[45] While much lower, the required energy input to form the transition 
state is provided by the binding energy from additional interactions between the 
substrate and active site. 
 
 
Figure 5 Induced fit enzyme model 
 
Daniel Koshland proposed the currently favoured induced fit model in 1958 
postulating that a change in the enzyme’s active site occurs in response to the 
substrate.[46] Initially, weak hydrogen bonding and hydrophobic/ionic interactions 
between a substrate and enzyme trigger a conformational change. This provides 
additional complementary positioned residues, which, through further interactions, 
stabilise the transition state (Figure 5).  
Other considerations for lowering activation energy involve the spatial properties 
of the active site. Reducing the entropy of the system involves aligning substrates and 
catalytic residues at a restricted and favourable orientation in the binding pocket. The 
binding of the substrate to the active site from the bulk water phase has an 
Active EnzymeSubstrate /Enzyme
Enzyme / 
Product
Conformation
Shift Reaction
Introduction  Chapter 1 | Literature Review 
 
 14 
accompanying entropy cost. As the system becomes more ordered, the free energy of 
the system is increased but is paid for by the binding energy obtained during catalysis.   
The space within the active site also contributes to enzymes having a high degree 
of stereo- and enantioselectivity. In 1948, Alexander Ogston suggested that prochiral 
molecules could react asymmetrically, provided the active site had a defined 
asymmetrical structure.[47] This led to the three-point attachment rule, which was first 
postulated to explain why only one type of radiolabelled α-ketoglutarate was detected 
from the reaction of aconitase with citrate; a symmetrical molecule (Scheme 11).   
 
Scheme 11 Top – Incorporation of labelled (red) acetate into α-ketoglutarate Bottom – 
Complementary vs non-complementary fit of substrate to active site.[42]  
 
A carbon (red) labelled acetate 33 was condensed with unlabelled oxaloacetate 34 
to produce prochiral citrate 35. Formation of isocitrate 36 followed by oxidative 
decarboxylation yielded α-ketoglutarate 37. Only products from the upper path were 
observed when analysing the product. The selectivity could be rationalised if the gem 
hydroxyl and carboxylate groups interacted at specific residues within the active site, 
effectively anchoring the substrate to always react at the same position.  
 
1.2.3. Methods of enzyme application in preparative biocatalysed reactions 
 
Enzymes can be employed as whole-cells, cell free extracts or isolated 
preparations. Initially workers were limited to whole-cells and crude extracts, 
nevertheless this still allowed advances in enzyme mediated asymmetric catalysis. For 
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example the formation of (R)-mandelonitrile in 1912 from benzaldehyde and 
acetonitrile was achieved using (oxynitrilase containing) extract of bitter almonds.[48] 
Microbial strains later discovered to contain alcohol dehydrogenases were utilised in 
seminal work by Prelog for the stereoselective reduction of ketones.[49] Regio- and 
stereoselective oxidative hydroxylation of progesterone by Aspergillus niger and 
Rhizopus arrhizus (CP450’s) led to a chemo-bio approach to the synthesis of 
hydrocortisone which previously required 40 distinct chemical steps.[50,51]  
 
 
Scheme 12 Stereoselective adduct formation from rabbit liver aldolase.[52] 
 
With the advent of improved methods of protein purification from the 1950’s 
onward, the possibility of using isolated enzymes was realised. This resulted in the 
utilisation of biocatalysts for stereoselective transformations with unnatural substrates. 
A particularly noteworthy transformation emerged from the Whitesides group in 1985 
(Scheme 12), where an isolated rabbit liver aldolase enabled the stereoselective addition 
of aldehydes and ketones to give chiral diols with high diastereoselectivity.[52] 
 
Despite the availability of isolated enzymes, whole-cells have seen continued use 
particularly where industrial scale up is concerned. For example L-DOPA, a drug used 
in Parkinson’s disease, is manufactured using a tyrosine-phenol lyase from E. herbicola 
(Ajinomoto, Japan)[53] and nicotinamide, a vitamin used for acne and niacin deficiency, 
is produced by a nitrile hydratase from R. rhodocrous (Lonza, Switzerland).[54] In 
several cases, where isolated enzymes are used, external redox co-factors (i.e. 
NAD+/NADH, NADP+/NADPH) and/or energy in the form of ATP are required to 
sustain the system.[41] These co-factors can be prohibitively expensive, particularly 
where stoichiometric equivalents are required. Conversely, in whole-cell systems, 
endogenous recycling is achieved through co-enzymes and cellular metabolism. Whole-
cells can also protect enzymes from toxic byproducts; for example many organisms 
produce catalase, which can neutralise hydrogen peroxide that would otherwise 
deactivate enzyme activity. 
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Scheme 13 Co-factor regeneration.[55] 
  
Co-factor regeneration strategies requiring only catalytic amounts of material 
have been developed using co-enzymes to work in tandem with isolated biocatalysts. 
For example, (Scheme 13) a xylose reductase from C. tenuis utilises NADH in the 
redox process. Instead of supplying stoichiometric quantities of the co-factor, which is 
unstable in solution, an auxiliary enzyme; formate dehydrogenase from C. boidinii was 
utilised[55]. In this case the formate is considered “sacrificial” as it is solely present to 
recycle NADH.  
Isolated enzyme preparations include solutions, lyophilised powder or 
immobilised on a solid support. The latter two are simple to use from a synthetic 
standpoint and have the advantages of cleaner product isolation and generally quicker 
reactions. Enzyme immobilisation provides a range of possibilities including higher 
substrate tolerance and, like lyophilisation, can provide greater functionality in organic 
solvent. Alexander Klibanov reported in 2001 that lipases such as porcine pancreatic 
lipase were found to retain partial activity in organic solvent in addition to having vastly 
improved thermal stability.[56] This was exploited in the stereoselective formation of 
chiral esters; a difficult reaction to perform in aqueous media due to the hydrolysis of 
esters to their corresponding acids and alcohols.  
Ultimately, the type of enzyme system employed will depend on factors including 
scale, cost and co-factor considerations, in addition to the type of reaction.  
 
1.2.4. Limitations of biocatalysts 
 
Enzymes have evolved to be highly specific for chemical transformations. The 
great majority of enzymes have operated under physiological conditions. This has 
resulted in a preference for ambient pH and temperature in an aqueous environment. 
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Deviating from these comparatively narrow parameters can result in enzyme 
denaturing/deactivation. A key property of organic molecules is that many are poorly 
water soluble, this is even exploited during conventional chemical purification in the 
reaction work up. However, biocatalytic reactions, where water is often required to 
achieve optimum activity, result in much lower effective substrate concentrations. 
The high enantioselectivity can also be a hindrance if the opposite enantiomer is 
required from a given transformation, a problem easily addressed in conventional 
catalysis by switching to the enantiomeric ligand. Substrate and product inhibition can 
also slow the rate of enzyme biotransformations.  
Most of these problems have been accepted as limitations of using wild-type 
proteins, specifically evolved to carry out limited functions required by nature. With the 
advent of recombinant DNA methods, directed evolution and protein engineering, many 
of the problems described have been addressed and even more selective and robust 
proteins can be expressed in much greater quantities than previously possible.  
1.3. Protein engineering 
 
Despite clear benefits to employing enzymes in chemical transformations, there 
are still many limitations with respect to stability, selectivity and the range of reactions 
that can be carried out. Advances in protein engineering have allowed the modification 
of residues in structurally relevant sites using a range of targeted evolution methods. 
 
1.3.1. Recombinant DNA for protein expression 
 
An early problem encountered using isolated proteins stemmed from the amount 
of material naturally expressed. Only small quantities of enzyme could be extracted 
from microbes, fungi, plants and animals, which presented a major obstacle for 
generalising the use of biocatalysts in chemical synthesis. This changed with the advent 
of molecular cloning techniques in the early 1970’s, where isolation of restriction 
endonucleases, DNA polymerases and DNA ligases combined with size exclusion 
purification techniques allowed heterologous protein expression for the first time. [57,58]  
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Figure 5 DNA cloning for heterologous expression.[59] 
 
In molecular cloning, a DNA strand containing genetic information to express a 
given protein is isolated using restriction endonucleases, phosphodiester bond cleaving 
enzymes, which act specifically at restriction sites on a given plasmid. DNA ligases can 
then join the strand into a restriction site of vector DNA creating a recombinant 
plasmid. Inserting the plasmid into a host organism such as E. coli results in populations 
of organisms also producing the recombinant DNA.[59] E. coli is often used as a host 
due to the fact it grows fast, is relatively benign and is amenable to cloning foreign 
DNA. In addition to cloning DNA, expression strains of E. coli have been engineered 
that accommodate for the unnaturally high protein loads arising from heterologous 
expression. This allowed for industrial scale production of proteases and lipases, which 
saw initial use in detergents (Novozyme, Henkel). 
 
1.3.2. The polymerase chain reaction 
 
First developed by Kary Mullis in 1983, the polymerase chain reaction (PCR) 
revolutionised molecular biology and has become an indispensible tool in protein 
engineering.[59,60] The technique allows for large scale cloning of DNA through multiple 
cycles of replication with up to millions of potential copies available from a single 
sequence. The technique differs from molecular cloning in that it doesn’t require 
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internal cellular machinery; instead utilising a thermostable DNA polymerase and 
thermal cycling. 
 
 
Figure 6 Outline of polymerase chain reaction (PCR) 
 
Firstly, the strand of DNA being replicated also known as the template is 
denatured and unwound by heating to 95 °C (Figure 6). After reducing the temperature 
to 45 °C complimentary single short strands of oligonucleotides called primers anneal to 
the template before the separated strands can re-bind. At 72 °C DNA polymerase 
isolated from thermostable Thermus aquaticus (Taq) extends the primers making a copy 
of the original complementary strand. This process is usually repeated 20-40 times and 
as DNA is replicated the new strands themselves are used as templates for subsequent 
cycles resulting in exponential amplification. 
PCR being a cheap, reliable and effective way of replicating specific sequences of 
DNA has resulted in many applications across modern biology, medicine and forensic 
science. It is a more efficient method of cloning DNA compared to molecular cloning 
and the DNA produced is also pure. By employing different primers, specific regions of 
genomic DNA can also be amplified, isolating regions of interest. Amplification of 
DNA samples has applications in forensic science where only trace amounts of genetic 
material may be available, the amplified sample can then be analysed through DNA 
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profiling. Medical applications of PCR include genetic profiling; where regions of an 
individuals DNA can be analysed to search for known mutations characteristic for a 
given disease. HIV can also be detected much earlier and treatment quantified using a 
variant method of PCR coupled with reverse transcriptase (RT-PCR).[61] Instead of 
screening for antibiotic markers that can take weeks to develop, blood can be screened 
directly for the viral RNA by amplifying the DNA complement produced by reverse 
transcriptase. 
 
1.3.3. Site-specific mutagenesis 
 
Site-specific mutagenesis is a structure based genetic engineering technique that 
involves altering one or more bases in the sequence to replace an amino acid with one 
of the 19 naturally occurring alternatives. Michael Smith first reported this method in 
1978 where mutated DNA was obtained by incorporating complementary 
oligonucleotides containing base mismatches.[62,63] This technique was initially adopted 
to improve enzyme stability with applications in synthesis. For example the thermal 
stability of a 3-isopropylmalate dehydrogenase was improved by introduction of a polar 
tyrosine residue resulting in additional protein surface hydrogen bonding.[64]  
 
 
Scheme 14 Lipase catalysed kinetic resolution of bulky alcohols[65] 
 
This approach was also later used to successfully augment stereoselectivity and 
catalytic activity. A mutated lipase from Burkholderia cepacia displayed a 40-fold 
greater E value and improved rate of reaction compared to the WT enzyme on alcohols 
with bulky substituents (Scheme 14).[65] 
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Figure 7 (a) Transition state H-pi interaction between Phe287 and (R)-1-phenyl-1-hexanol (b) 
steric repulsion in partially fluorinated (R)-1-phenyl-1-hexanol.[65] 
A double mutant (I287F/I290A) was found to have improved activity on (R)-1-
phenyl-1-hexanol 43a. Ala290 avoided previous collisions of the alkyl chain with Ile, 
while Phe287 substitution resulted in attractive H-π interactions. The positive effect of 
the latter was supported by much poorer activity of the fluorinated analogue where 
aromatic interactions could not take place (Figure 7).  
Specific mutagenesis is limited in that knowledge of the individual protein 
structure is necessary in order to be carried out. Owing to the individual variation and 
complexity of enzymes in addition to a lack of clear correlation between sequence and 
function, a general strategy for structural optimisation has yet to be realised.  
 
1.3.4. Random mutagenesis and the dawn of directed evolution 
 
Random mutagenesis can be employed without prior knowledge of the protein 
structure depending on the technique employed. Error-prone PCR (epPCR) is the most 
common method of developing random mutations and involves incorporation of 
incorrect base pairs during DNA replication. This can be achieved by a number of 
methods including using DNA polymerase lacking a proof reading module thereby 
being more prone to errors, by increasing the amount of MgCl2 in the reaction, altering 
the concentration of available dNTPs or using mutator strains. Developed by Pim 
Stemmer, DNA shuffling is an efficient method for the rapid library expansion that 
digests mutated DNA strands into oligonucleotides of 50-100 bp that are then combined 
and extended through conventional PCR.[66] Saturation mutagenesis is another popular 
method of randomisation at specific residues using degenerate oligonucleotides, 
however knowledge of the protein structure is required. Early examples of mutagenic 
libraries produced enzymes possessing greater thermostability[67] and resistance to 
chemical oxidants.[68]  
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Figure 8 Schematic representing conventional iterative mutagenesis 
 
Directed evolution involves iterative rounds of random mutagenesis following 
selection of mutants with desired properties (Figure 8). The first reported example 
using successive rounds of mutagenesis improved the thermostability of a kanamycin 
nucleotidyltransferease from B. stearothermophilus.[69] The functioning temperature 
was increased through two rounds of mutagenesis. Enzymes containing a double mutant 
tolerated operating temperatures of 70 °C, a considerable improvement over 47 °C for 
the WT.  
However, iterative mutagenesis was not explored further until seven years later 
with Francis Arnold’s seminal work on the protease Subtilisin E.[70] Through 4 rounds 
of mutagenesis and screening, Arnold’s group, developed a variant containing 10 
mutations with 256 times the activity of the wild-type enzyme in 60 % DMF. 
Additionally, it was demonstrated that the mutant could catalyse the synthesis of the 
peptide poly(L-methionine) in 70 % DMF where the wild-type had no measurable 
activity. Enzyme catalysed reactions in organic solvent are industrially attractive owing 
to higher solubility of hydrophobic substrates and suppression of unwanted water-
dependent side reactions. Organic solvent often results in loss of enzyme activity. 
However, in this case mutations around the active site resulted in a mutant enzyme 
almost as efficient in high concentrations of DMF as the wild-type enzyme in an 
aqueous environment. 
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 1.3.5. Highlighted examples of directed evolution 
 
Early work focused on improving enzyme thermal stability to be more suited to 
industrial operating conditions. Proteases in particular were given a great deal of 
attention due to the need for stable proteins in detergent applications.[71] Additional 
work was undertaken utilising directed evolution to increase the thermal stability of 
several different enzymes including esterases[72], peroxidases[73] and amylases.[74] 
 
 
Scheme 15 Lipase catalysed resolution of chiral ester[75] 
 
Interest in augmenting the catalytic parameters of enzymes for use in organic 
synthesis was the driving force for the first reported example to improve 
enantioselectivity (Scheme 15).[75] A lipase from Pseudomonas aeruginosa used in the 
kinetic resolution of racemic ester 45 showed marginal selectivity for formation of the S 
product (E = 1.2). Sequential single point mutations through 4 rounds of mutagenesis 
resulted in a lipase with over 10-fold stereopreference for the S isomer. 
 
Figure 9 Sequential gene mutagenesis of Pseudomonas aeruginosa lipase[76] 
This was further improved during subsequent work, which used a combined 
approach of epPCR, saturation mutagenesis and targeted mutagenesis (Figure 9).[76] 
O
R
O
NO2
Lipase
R
OH
O
R
O
O
HO
NO2NO2
 rac-45 (S)-46 (R)-47 48
Introduction  Chapter 1 | Literature Review 
 
 24 
After the S115F substitution was found to have a significant effect on the E value of the 
wild-type enzyme, the substitution was introduced in other mutants. What was 
particularly noteworthy is that the S115F substitution had varying contributions to 
stereoselectivity depending on other mutations present. The introduction of S115F had a 
much greater effect on selectivity with V47G compared to F259L, a seemingly more 
selective mutant. This demonstrated that when using a combined approach, the routes to 
the most selective enzyme might arise from synergistic effects involving previously less 
selective variants. 
An impressive example using directed evolution to augment both stereoselectivity 
and substrate specificity concerns a 2-keto-3-deoxy-6-phosphogluconate (KDPG) 
aldolase from E. coli.[77] The wild-type enzyme catalysed the reversible addition of 
pyruvate to an aldehyde stereoselectively forming a carbon-carbon bond and delivering 
the phosphorylated precursor 51 to the D-sugar (Scheme 16). A combination of epPCR 
and DNA shuffling was used to screen for variants that accepted non-phosphorylated 
substrates in addition to showing opposite enantioselectivity for the aldehyde.   
 
 
Scheme 16 Directed evolution of a KDPG aldolase to tune stereoselectivity and substrate 
specificity[77] 
 
Of the initial 2400 mutant population screened, less than 0.5 % showed improved 
2-keto-3-deoxy-galactonate (KDG) activity. Four genes found with improved activity 
were combined using DNA shuffling and the resulting library was assayed with more 
active mutants being combined and re-screened. A total of four generations were 
assayed and produced in this manner with a similar approach taken to probe 
stereoselectivity. The target reaction was screened for using the aldol product 54 as a 
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substrate and monitoring pyruvate formation with a coupled lactate dehydrogenase 
(LDH) and following reduction of NADH spectrophotometrically. A resulting variant 
produced with 4 active mutations (T84A, I92F, V118A and E138V) showed good 
activity with the non-phosphorylated galactonate and produced the sugar precursor with 
perfect diastereo control.  
Sialic acid aldolase was mutated in a semi-rational approach to extend the 
substrate scope beyond N-acetylmannosamine 56.[78] Using crystallographic data 
obtained from the Haemophilus influenzae enzyme, which contained 35 % sequence 
identity and 59 % similarity, three key residues were identified that interacted with an 
inhibitor 4-oxosialic acid. 
 
 
Scheme 17 Directed evolution of an aldolase for synthesis of sialic acid mimetics[78] 
 
The equivalent residues in the E. coli enzyme; Asp191 Glu192 and Ser208 
underwent saturation mutagenesis and were screened against a synthesised analogue 59 
(Scheme 17), with the assumption that an active mutant would also catalyse the forward 
reaction. A singe mutation E192N was observed to have a 50-fold improvement in 
substrate specificity (kcat/KM) for 59 over the wild-type enzyme. 
 A combined deracemisation system consisting of an engineered monoamine 
oxidase (MAO-N) from A. niger and a non-selective chemical reducing agent allowed 
for the production of enantiomerically pure chiral amines, which are important building 
blocks in the synthesis of pharmaceuticals (Scheme 18).[79] 
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Scheme 18 Dynamic kinetic resolution using a selective amine oxidase and non-selective 
reducing agent[79] 
 
Depending on the selectivity of the enzyme employed, either isomer could be 
obtained in high enantiomeric purity from the racemate. This process is a key example 
of an engineered enzyme used in industrial biocatalysis and was later patented by 
Ingenza.[80]  
1.4. Examples of industrial application for engineered biocatalysts  
 
Protein engineering has delivered selective enzymes that are stable to harsh 
processing conditions. Their comparatively high activity per unit mass and ease of 
removal compared to whole-cells has resulted in engineered biocatalysts becoming 
economically viable in the industrial sector. The stereoselective reduction of ketones 
using isolated ketoreductases (KREDs) is believed to have largely replaced whole-cell 
and metal-ligand based approaches.[81]   
 
Scheme 19 Enzymatic route to the key side chain of atorvastatin[82] 
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KREDs have been used in several stages during the synthesis of atorvastatin 68, 
an active pharmaceutical ingredient (API) present in Pfizer’s blockbuster cholesterol-
lowering drug, Lipitor (Scheme 19).[82,83] The process highlighted involves 3 
biocatalytic steps, two KRED stereoselective reductions providing intermediates 63 and 
66 in addition to a halohydrin dehalogenase (HHDH) to form 64. 
 
 
Scheme 20 Chemo/bio routes to sitagliptin[84]  
 
Sitagliptin 70 (marketed as Januvia, Merck), is a drug used to treat 
hyperglycaemia in patients with type-2 diabetes. The final step of synthesis involves the 
stereoselective transamination of prositagliptin 69. A process utilising an engineered S-
selective transaminase increased the overall yield with greater stereoselectivity in 
addition to replacing all transition metals.[84] Additionally, the bioctalytic method used 
much less waste and increased overall process efficiency by up to 53 %.[85]    
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Scheme 21 Comparison of bio/chemo routes to pregabalin[86] 
 
Pregabalin 73 is the API in Lyrica (Pfizer), a drug used in the treatment of 
epilepsy, neuropathic pain and general anxiety. A chemoenzymatic approach to process 
optimisation involved the stereoselective hydrolysis of racemic 71 and recycling of the 
unwanted isomer back to the racemate in a relatively benign manner.[86] The previous 
process cleaved an ester and reduced the cyano compound to a racemic amine before 
recrystallizing the desired enantiomer as a mandelic acid salt 75. The improved process 
prevented late-stage loss of 50 % product through classical resolution and lowered the E 
factor from 86 to 17, increasing the overall yield up to 40-45 %.  
 
Scheme 22 Deracemization of racemic amino acid drug candidate.[87] 
The S-amino acid 76 is a key intermediate in a candidate antidiabetic drug being 
developed by Bristol-Meyers Squibb.[87] A deracemization using a selective R-oxidase 
and S-dehydrogenase allowed the desired enantiomer S-76 to be fully resolved. 
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1.5. Oxidative enzyme transformations 
 
Oxidations are a key reaction in organic synthesis and are used to access many 
functional groups including: aldehydes, ketones, imines, amides and carboxylic acids. 
Transition metal based approaches to oxidations have been traditionally adopted, often 
requiring stoichiometric quantities of oxidant.[88] However, many metal containing 
oxidants such as Jones/Sarrette (chromium) and Tollen’s (Silver) reagent are highly 
toxic and produce significant waste. Other metal free organic oxidations are available 
such as the Swern (sulphur) and Dess-Martin (hypervalent iodine) but produce toxic 
byproducts and are potentially explosive.  
The need for more benign methods of chemical oxidation has led to approaches 
using less toxic metal. Methods using stoichiometric amounts of organic oxidant with a 
catalytic amount of metal have been successful with palladium[89] and copper.[90] An 
important discovery by Milstein et al.[91] utilised a novel ruthenium pincer catalyst in an 
oxidative amide coupling with refluxing basic water. This process producing only H2 as 
a side product had excellent atom economy and was further utilised for the oxidation of 
unactivated primary alcohols.[92] Gold nanoparticles using molecular oxygen have also 
successfully been used in the synthesis of amides.[93] These greener approaches still 
have inherent limitations related to selectivity, operating temperatures, expensive 
catalysts and unwanted side-reactions preventing general adoption.   
The chemo-, regio- and stereoselectivity of enzymes make bio-oxidations useful 
for clean formation of product in fewer steps by avoiding unnecessary 
protection/deprotection. There are many examples of biocatalysed oxidation reactions 
using a range of enzymes that are comparatively benign and practically metal free.[94]  
 
1.5.1. Classes of oxidative enzymes 
 
Dehydrogenases are amongst the most common enzymes used in oxidation 
reactions and are the most studied. They catalyse the reversible oxidation of alcohols 
and amines utilising a NAD(P)+ cofactor. Alcohol dehydrogenases (ADH) have been 
extensively studied for the oxidation of primary and secondary alcohols.[95] ADH from 
horse liver (HLADH) was one of the first exploited for use in organic synthesis, due to 
a broad substrate tolerance and S-selectivity.[96] 
Oxidase enzymes are also available to catalyse the transformation of alcohols, 
aldehydes and amines. Most alcohol oxidases (AlcOX) are flavin-dependent where 
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FAD is the primary hydride acceptor. Glucose oxidase (GluOX) is a very well known 
flavoenzyme responsible for the oxidation of β-D-glucose, however its substrate scope is 
significantly limited.[97] A Cu2+-dependent galactose oxidase (GOase) has a 
comparatively broader substrate scope, which has been further enhanced through 
protein engineering.[98,99] Laccases are a member of the blue-copper oxidases and 
generate radicals through the single electron abstraction of phenolic type 
compounds.[100] Poor redox potentials mean laccase cannot oxidise alcohols alone, 
however they can re-oxidise activated mediators such as HBT 78, ABTS 79 and 
TEMPO 80 (Scheme 23). Laccase-mediator-systems (LMS) produce water instead of 
H2O2 as seen in other oxidases. In some cases LMS have replaced hypochlorite as a 
greener terminal oxidant but low turnover is still a major limitation.[101]  
 
Scheme 23 LMS for alcohol oxidation[100] 
 
Oxygenases catalyse the reductive activation of molecular oxygen, the resulting 
peroxide and protein bound metal complex can catalyse selective hydroxylations, 
epoxidations and Baeyer-Villiger reactions.[102,103] Cytochrome P450 monooxygenases 
utilise an iron-heme complex, where the active species 82 is formed through NAD(P)H 
mediated reduction of O2 (Scheme 24).[104]   
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Scheme 24 Simplified P450 monooxygenase active species formation 
 
Peroxidases can perform similar reactions to oxygenases but require hydrogen 
peroxide to regenerate their active prosthetic group which, in addition to iron, can 
contain selenium, vanadium or manganese. [105,106] Peroxidase from Agroybe aegerita 
(AaP) has been discovered as a potential replacement for Caldariomyces fumago 
(CPO), a well-documented enzyme for oxidations and oxyfunctionalisations that isn’t 
economically viable for preparative transformations.[107] 
 
1.5.2. Enzymatic alcohol oxidations 
 
Single-step and “through oxidations” of primary alcohols to aldehydes and 
carboxylic acids are a cornerstone of organic synthesis. Biocatalytic oxidations of this 
class have accordingly received a great deal of interest. Conversely, oxidation of 
secondary alcohols destroys chirality and has received less attention due to the lack of 
complexity in the planar products. However, secondary alcohol oxidation plays an 
important role in the production of enantiopure alcohols through dynamic kinetic 
resolutions.[95]  
 
1.5.2.1. Bio-oxidation of primary alcohols to aldehydes 
  
Preventing the over-oxidation of primary alcohols to carboxylic acids is a major 
challenge due to the reactivity of aldehydes. This is a particular problem in whole-cells, 
where co-factors are readily regenerated and other oxidative enzymes may be present. 
An effective solution utilised by Buhler et al.[108] for the xylene monooxygenase-
facilitated production of 3,4-dimethylbenzaldehyde, involved incorporation of a less 
polar organic solvent to selectively partition the aldehyde for in situ product extraction.  
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Scheme 25 Reaction engineering for controlled alcohol oxidations.[109] 
 
This process was also used in the selective oxidation of aliphatic and aromatic 
alcohols using H2O or H2O/isooctane with acetic acid bacteria containing ADH 
(Scheme 25).[109] Depending on the reaction conditions employed, the aldehyde or acid 
could be selectively obtained in excellent yield. 
 
 
Scheme 26 Two-step one-pot chemo/stereoselective alcohol oxidation and aldol 
biotransformation[110]  
 
Another method of aldehyde conservation involves a multi-enzyme cascade where 
the aldehyde is utilised in a second reaction before over-oxidation can occur. A one-pot 
cascade utilising AlcOx from Pichia pastoris and 2-deoxyribo-5-phosphate aldolase 
(DERA) allowed for the selective oxidation of the alcohol 88, followed by a 
stereoselective aldol reaction to deliver 90 in modest yield (Scheme 26).[110] The vinyl 
group also remains intact throughout this process, highlighting the benefits of 
employing a chemoselective biocatalyst. 
LMS have facilitated the successful single oxidation of a range of benzyl alcohols 
with ABTS[111] and TEMPO[112] in quantitative yields. 
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1.5.2.2. Bio-oxidation of primary alcohols to carboxylic acids 
 
The biocatalytic oxidation of primary alcohols to carboxylic acids has largely 
been dominated by whole-cell systems. This is due to the endogenous regeneration of 
co-factors such as NAD(P)+ that would have to be supplemented through other means in 
isolated enzymes. Acetic acid bacteria containing ADH III and an aldehyde 
dehydrogenase (AldDH) have been used for the multi-gram scale “through” oxidations 
of several alcohols (Scheme 27).[113,114] These reactions also displayed stereoselectivity 
for some chiral substrates allowing for large scale kinetic resolutions.[115-118] Other 
organisms expressing ADH’s have been used in the bio-oxidation of furan alcohols to 
give the corresponding acids including previously discussed platform chemical 
candidate FDCA 26 (Scheme 27).[119,120] 
 
 
Scheme 27 Examples of whole-cell catalysed “through oxidations” and kinetic resolutions of 
aliphatic and aromatic alcohols (E = enantiomeric ratio).[113-120] 
While less prevalent than whole-cells, there are still several examples of processes 
utilising purified enzymes for the oxidation of primary alcohols. In an early example 
reported by Wong et al., isolated HLADH was used for the selective resolutions of 1,2-
diols to α-hydroxy acids (Scheme 28).[121]  
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Scheme 28 Isolated HLADH used for kinetic resolution of α-hydroxy acids[121]  
Coupled with an AldDH, both enzymes utilised an equivalent of NAD+, which was 
regenerated with an α-ketoglutarate/glutamate dehydrogenase (GluDH) system. In 
addition to 1,2-diols, the HLADH catalysed oxidation of 1,4 and 1,5-diols has led to the 
formation of enantiopure lactones through the spontaneous cyclisation of the primary 
aldehyde followed by additional oxidation of the hemiacetal.[122,123] 
 
 
Scheme 29 ADH catalysed desymmetrisation of meso- 1,4- and 1,5-diols[122,123] 
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Lactones were produced at gram scale with good to excellent conversions. The 
desymmetrisation approach is interesting as, unlike in conventional kinetic resolutions, 
the desymmetrisation allows for potentially 100 % of a given enantiomer to be formed 
in the presence of a selective oxidant. 
 
1.5.2.3. Regioselective bio-oxidation of polyols 
 
Enzymatic discrimination of substrates bearing multiple reactive moieties is a 
highly desirable trait in improving atom efficiency and lowering waste. Regioselective 
chemical oxidation of carbohydrates has to contend with multiple functional groups, 
which requires extensive protection/deprotection to avoid unwanted reactions. Many 
polyol oxidases and dehydrogenases have been used for the oxidation of carbohydrates 
including galactose[124], glucose[125] and lactose[126] on a preparative scale. Selective 
polyol oxidases have seen multiple industrial applications. Fructose is commercially 
used in the food industry for its sweetening properties, but also has important 
applications as a feedstock for platform chemical replacements (i.e. FDCA). The Cetus 
process utilises a pyranose-2-oxidase (P2O) followed by chemical dehydrogenation to 
produce pure fructose from glucose.[127] 
 
 
Scheme 30 Microbial Glucoobacter oxidans regioselective oxidation of polyols[128-131] 
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L-Ascorbic acid 115 (L-AA) otherwise more widely known as vitamin C is an 
important dietary supplement that has been traditionally manufactured using the 
Reichstein process; a largely chemical method of manufacturing L-AA from D-
glucose.[128] An early step in the synthesis involves the fermentation of D-sorbitol 113 to 
L-sorbose 114 using Gluconobacter oxidans (Scheme 30), biotechnological advances 
have also allowed for further microbial substitution of steps.[132] Gluconobacter oxidans 
was also found to regioselectively oxidise a number of polyols including ribitol 118[130], 
glycerol 116[129] and N-butylglucamine 120.[131]  
 
1.5.2.4. Bio-oxidation of secondary alcohols (kinetic resolution) 
 
The oxidation of secondary alcohols isn’t considered as synthetically interesting 
as primary alcohols due to the loss of chiral information. A selective oxidase can allow 
accumulation of the opposite enantiomer in a kinetic resolution, however a maximum of 
only 50 % yield can be achieved. Conversely, enantiospecific reduction of a prochiral 
ketone could result in 100 % conversion. Kroutil et al. reported preparative scale kinetic 
resolutions of several aliphatic and aromatic S-alcohols from Rhodococcus ruber 
expressing ADH-A (Scheme 31)[133] This was the first example using preparative scale 
whole cell oxidation of a secondary alcohol tolerating acetone as a co-substrate for 
NAD+ regeneration.  
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Scheme 31 Kinetic resolution of secondary alcohols using Rhodococcus ruber[133]  
 
The “meso trick” refers to the selective transformation of a symmetrical prochiral 
compound to give exclusively one enantiomer. This approach has limited applications, 
as meso-compounds are relatively scarce. Regardless there are examples in the literature 
describing the desymmetrization of prochiral meso-diols using selective 
dehydrogenases.[116,134] 
 
 
Scheme 32 Desymmetrization of meso-2,4-hexanediol using ADH-A from Rhodococcus 
ruber[135] 
 
Further work from Kroutil et al. has also demonstrated the meso trick on 2,5-
hexanediol 128 also using the previously described Rhodococcus ruber system (Scheme 
32).  
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1.5.2.5  Alcohol deracemizations 
 
As previously discussed (Scheme 22), deracemizations are concerned with 
stereoinversion of the unwanted enantiomer through a selective oxidation/reduction. 
Ideally, both enzymes should be complementarily stereoselective to a high degree, 
though a minimum of one stereoselective step is essential. With only one stereoselective 
enzyme, enrichment of one enantiomer will occur, resulting in more cycles (more co-
factor required) to achieve deracemization.  
 
 
Scheme 33 Selective deracemization of secondary alcohols through stereoinversion[136,137] 
 
A range of simple aliphatic and aromatic secondary alcohols could be 
deracemized to the desired enantiomer in quantitative conversion through selective 
ADH oxidative/reductive cascades on a multi-gram scale (Scheme 33).[136,137] It is 
important to note that regeneration systems for the cascades require enzymes utilising 
different co-factors (i.e. NAD+/NADP+) to avoid co-factor competition and futile cross-
activity.  
 
1.5.3. Enzymatic amine oxidations 
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1.5.3.1. Amino acid bio-oxidations 
 
Oxidations of L-amino acids comprise some of the earliest examples of 
biocatalytic amine oxidations. Amino acid dehydrogenases (AADH) such as L-alanine 
dehydrogenase[138] are highly L-selective and have been used in the successful kinetic 
resolution of racemic α-amino acids. Much like ADHs, AADHs rely on NAD(P)+ 
recycling to drive the reaction equilibrium. An interesting alternative to the 
conventional methods of co-factor regeneration involved an electrochemical system 
using method of NADH re-oxidation with an anode during the stereoinversion of L-
alanine.[139] The selective oxidation yielded pyruvate, which was recycled through 
addition of a large excess of ammonia followed by cathodic reduction of the resulting 
imine.  
Amino acid oxidases (AAOx) comparatively have less problematic co-factor 
dependencies. For example the D-AAOx catalysed quantitative conversion of D-
phenylalanine into phenylpyruvic acid was achieved through bubbling oxygen directly 
into the reaction.[140] AAOxs also catalyse a wider range of amino acids in high 
stereoselectivity resulting in valuable catalysts for the production of chiral α-amino 
acids. The oxidative deamination of cephalosporin C is an industrial example of D-
AAOx in the production of 7-aminocephalosporonic acid 139, an important semi-
synthetic antibiotic building block. Previously, the highlighted process (Scheme 34) 
was ran alongside a conventional chemical route at GlaxoSmithKline with life cycle 
assessments claiming up to 60 % reduction in environmental cost.[141]   
 
 
Scheme 34 Industrial enzymatic route to 7-ACA[141] 
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Deracemizations and DKRs using AAOx for the production of chiral amines have 
also gained considerable attention. Turner et al. developed several one-pot chemo-
enzymatic cascades using a stereoselective D- or L-AAOx and a non-selective reducing 
agent (NaBH4, NH3-BH3 or NaCNBH3) to regenerate the racemic starting material for a 
range of amino acids (Scheme 35).[142-144] 
 
Scheme 35 Chemoenzymatic DKR of chiral amino acids.[142-144] 
 
1.5.3.2. Amine bio-oxidations 
 
While AAOxs have allowed for the production of a range of chiral amino acids, 
they are limited by their natural substrates and are unable to oxidise amines. As 
mentioned previously, monoamine oxidases (MAO) are a class of oxidative 
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flavoenzyme with the ability to facilitate deracemization of a range of primary, 
secondary and tertiary amines with much work by Turner et al. contributing toward 
industrial commercialization.[79] Furthermore, work in the group of Turner produced a 
range of mutated variants of MAO from A. niger that significantly broadened the 
substrate scope. Highlights include a variant (D5) able to catalyse the oxidative 
desymmetrization of various pyrrolidines; subsequent or in situ cyanide treatment of the 
resulting imines yielded a range of substituted prolines with exceptional optical 
purity.[145] Variants D9 and D11 allowed for the oxidative deracemization of a range of 
tetrahydro-β-carbolines (THBC), a group of natural bio-active alkaloids present in 
multiple pharmaceutical compounds such as the anti-hypertensive reserpine 150.[146]    
 
 
Scheme 36 MAO-N variant catalysed deracemization of THBCs[146]   
  
Strategies for amine oxidation like in the MAO examples often quickly consume 
the resulting imine through in situ chemo reduction or nucleophilic attack; this is to 
prevent unwanted hydrolysis of the imine in aqueous conditions and subsequent 
reactivity of the generated aldehyde. There are examples however where aldehyde 
formation in aqueous conditions has been exploited. MAO initiated oxidation of 
dopamine followed by spontaneous Pictet-Spengler condensation was used to produce 
norlaudanosine 153, a dopamine-uptake inhibitor (Scheme 37).[147] 
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Scheme 37 MAO-triggered Pictet-Spenglar production of norlaudanosine[147] 
 Transaminases (TAs) have been utilised as tools to access non-racemic α-chiral 
amines. Kroutil et al. have presented two approaches using either a kinetic resolution 
(with a carbonyl-containing co-substrate as the amine acceptor) or direct asymmetric 
transamination of the ketone.[148] The latter method is particularly interesting as 100 % 
of the product is potentially attainable (Scheme 38).  
 
 
Scheme 38 Asymmetric synthesis of chiral amines using transaminase[148] 
  
Reversibility of amino group transfer in addition to substrate inhibition was 
identified as a key challenge. A solution to the former was approached by Truppo and 
Turner by using pyruvate as an amino group acceptor coupled with an AAOx, 
irreversibly oxidising the co-product while regenerating pyruvate (Scheme 39).[149] 
 
 
Scheme 39 Racemic amine resolution coupled with catalytic pyruvate and AAOx[149] 
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1.5.4 Enzymatic aldehyde oxidations 
 
Compared to alcohol oxidations, the bio-oxidations of aldehydes have garnered 
much less interest and are less studied. The first reported aldehyde bio-oxidation 
involved the NAD(P)+ dependent oxidation of formaldehyde by HLADH.[150] HLADH 
will oxidise other aldehydes to the carboxylic acid in presence of equimolar 
concentrations of NAD(P)+, however the NAD(P)H catalysed reduction of the starting 
material is an unwanted side reaction.[151] ADH catalysed aldehyde oxidation has been 
speculated to proceed by the hydrated form of the substrate thereby allowing access to 
an abstractable hydride by the oxidised nicotinamide co-factor.[152] Other aldehyde 
oxidations have been described in this chapter previously as a consequence of the 
through oxidations of alcohols largely by acetic acid bacteria and some isolated ADHs.  
Naturally occurring aldehyde oxidising enzymes primarily consist of aldehyde 
dehydrogenases (AldDHs), which are largely similar to ADHs. The key mechanistic 
difference between the enzymes involves an active site cysteine residue that catalyses 
oxidation through a thiohemiacetal and thioester intermediate (Scheme 40).[153] 
 
 
Scheme 40 Proposed mechanism for cysteine catalysed AldDH oxidation[153] 
  
 Industrial applications of AldDH are rare. A dual ADH/AldDH coupled 
disproportionation approach initially employed on a preparative scale for (Z,Z)-nona-
2,4-dienal, was extended to metabolites of linoleic acid for industrial production of 
detergents and polymers.[154] Aldehydes are not typically substrates for oxidases 
although a key exception is the xanthine oxidase class of molybdenum hydroxylase 
enzymes. 
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1.6. Molybdenum-dependent oxidoreductases 
 
Oxidation of functional groups including aldehydes and N-heterocycles by various 
metabolising enzymes, most notably CYP450’s is an important stage in drug 
metabolism. Oxidation creates a handle for incorporation of more easily excreted bulky 
groups (glucuronidation, sulfation) in phase II metabolism. Molybdenum hydroxylases 
are a family of oxidoreductase enzymes widely distributed throughout nature. They are 
complex flavoproteins, principally involved in the mammalian bioconversion of 
pharmaceuticals and xenobiotics during phase I metabolism. They exist as monomers or 
dimers of hetero-trimers and are comprised of a molybdenum cofactor (Moco), FAD 
and a pair of [Fe-S] containing redox centre electron reservoirs (Figure 10).[155]  
 
 
Figure 10 Internal electron transport of molybdenum hydroxylases[155] 
 
The molybdenum is correctly positioned within the active site through a bound 
pterin moiety, which is assembled and loaded as a Mo-pterin complex (figure 11) by 
the requisite insertase chaperone.[156] Moco containing enzymes are divided into three 
families depending on the structure of the cofactor: DMSO reductases, xanthine 
oxidases and sulphite oxidases.[157] In E. coli, the xanthine oxidase family is comprised 
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of xanthine oxidoreductases (XOR) and aldehyde oxidases (AO), which are 
characterised by a molybdopterin-cytosine-dinucleotide (MCD) cofactor.   
   
 
 
Figure 11 Structure of the pyranopterin molybdenum cofactor (Moco) in the xanthine oxidase 
family 
 
In the xanthine oxidase family, the molybdenum exists in a distorted square 
pyramidal configuration with a double bound oxygen group in the apical position. The 
two pterin sulfurs in addition to a water derived hydroxyl group and terminal Mo=S 
occupy the equatorial plane. A number of amino acid residues are highly conserved 
throughout the molybdenum-containing domain and are involved in Moco coordination 
including Gln211, Phe242, Gly243, Arg350 and Glu692 (Ec PaoABC 
numbering).[157,158]  
 
 
Figure 12 Sequence alignment of Moco domain of 14 bacterial molybdenum hydroxylases 
including conserved (blue arrows) and non-conserved (red arrows) residues.[158] 
 
Non-conserved residues correlate to differences in substrate binding in the active 
site domain. Enzymes with preference for aldehyde oxidation lack phenylalanine 
residues at position 352 and have conserved Leu246, Glu354 and Arg440 residues.  
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1.6.1. Xanthine oxidase mechanism 
 
Through 18O labelling and EPR experiments, molybdenum hydroxylases have 
been found to incorporate oxygen from surrounding water during the biooxidation of 
aldehydes and imines.[157] The generally accepted reaction mechanism begins with co-
ordination of the substrate to the Moco redox centre of the enzyme active site. 
Following deprotonation by a key neighbouring glutamate residue, the Moco-bound 
hydroxide ion attacks the substrate and electron transfer leads to reduction of Mo(VI) 
166 to Mo(IV) 167. The FAD sub unit in turn becomes reduced, this can occur either 
directly, or through the Fe-S cluster, which also acts as an electron sink.[159] The Moco 
then becomes re-oxidised and electrons are passed from reduced flavin to either 
molecular O2 (oxidase) or NAD+ (dehydrogenase).[160] Nucleophilic attack from external 
water on the electron deficient intermediate 167 delivers the oxidised product while 
restoring the Mo-pterin (Scheme 41).[161] 
 
 
Scheme 41 General molybdenum hydroxylase mechanism for benzaldehyde oxidation[161] 
 
1.6.2. Xanthine oxidoreductase (XOR) 
 
XOR participates in purine catabolism, notably in the formation of xanthine from 
hypoxanthine and then further oxidation to uric acid (Scheme 42).[155]  
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Scheme 42 Hypoxanthine to uric acid XOR biooxidation 
 
XOR is primarily found in the liver but in mammals is more distributed 
throughout the body and is present in the small intestine and mammary tissue.[162] XOR 
can exist in two forms from the same gene: xanthine oxidase (XO) and xanthine 
dehydrogenase (XDH). The subclasses vary in the type of substrates accepted and the 
cofactor utilised. XO utilises molecular oxygen whereas XDH utilises NAD+. 
 
 
Figure 13 Crystal structure of bovine XOR (PDB id: 1FIQ), grey = FAD domain, green and 
blue = Fe-S 1 and 2 domains respectively and red = molybdenum substrate binding domain.[163] 
 
Molybdenum hydroxylase Mo-OH groups attack electron deficient carbons alpha 
to the nitrogen in aromatic N-heterocycles. However, xanthine oxidoreductase’s 
substrate scope is comparatively limited compared to aldehyde oxidase. Regardless, 
XOR has been reported to oxidise a number of imine-containing drug molecules 
(Figure 14). [162,164-167] 
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with a fold resembling that found in vanyllic aldehyde
oxidase [3] (this FAD binding domain is absent in the
D. gigas enzyme [1]). Finally, the molybdenum-binding
portion of the protein is at the C-terminus (or CoxL
subunit), with the molybdenum center at the interface
of two elongated domains that lie across one another
at an angle of approximately 90!.
Scheme 1. Reaction stoichiometries for the monooxygenases (A) and
molybdenum hydroxylases (B).
Fig. 1. The topology of xanthine oxidoreductase. (A) The structure of the bovine enzyme [3], with (from the N-terminus) the Fe/S I and II domains
(green and blue, respectively), the FAD domain (gray) and the molybdenum-binding portion of the protein (red). The representation was rendered in
MolScript using file 1FIQ.pdb from the Protein Data Bank. (B) Schematic representation of the homologies that exist among the molybdenum
hydroxylases. The FAD domain is absent in the D. gigas aldehyde oxidoreductase [1]. In the R. capsulatus xanthine dehydrogenase the iron–sulfur
and flavin-binding portions of the protein constitute one subunit (XdhA), and the molybdenum-binding portion a second (XdhB), In the O.
carboxydovorans CO dehydrogenase [5], the iron–sulfur centers are together in one subunit (CoxS), the flavin in a second (CoxM) and the
molybdenum in a third (CoxL).
108 R. Hille / Archives of Biochemistry and Biophysics 433 (2005) 107–116
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Figure 14 Pharmaceutical compounds metabolised by XORs[162,164-167] 
1.6.3. Aldehyde Oxidase (AO) 
 
The other primary class from the xanthine oxidase family, AO is contained within 
the cytosol of tissues and is found within several living species. It is almost identical to 
xanthine oxidoreductases in terms of key functional moieties, however AO exists 
exclusively in a single form, utilising molecular O2 as an electron acceptor and 
generally has a broader substrate range for redox biotransformations compared to XOR. 
AO is known to metabolise a number of aliphatic and aromatic aldehydes to the 
corresponding carboxylic acids such as retinal into retinoic acid.[168] AO also oxidises a 
number of imines. In addition to the compounds in Figure 14, a range of other 
substrates including anti-malaria compounds such as Quinine 180 are metabolised 
(Figure 15). 
 
 
Figure 15 Selection of pharmaceutical compounds metabolised by AO 
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Periplasmic aldehyde oxidase (PaoABC) from E. coli has been identified as an 
unusual member of the aldehyde oxidase family by Leimkühler and co-workers.[158,169] 
Kinetic characterisation revealed activity with a broad range of aldehydydes, with a 
preference for aromatic aldehydes. It is believed that PaoABC plays an important role in 
the detoxification of aromatic aldehydes in the periplasm. It is the first example of an E. 
coli protein containing a MCD co-factor and the first structurally characterised 
heterotrimer of the XO family.  
 
 
Figure 16 Crystal structure of E. coli PaoABC[158] 
The crystal structure was similar to those of other characterised members of the 
XO family however an unexpected [4Fe-4S] cluster was identified in subdomain near to 
FAD in the protein (green Figure 16). This is believed to be involved in regulation of 
the oxidation state of the FAD during electron transfer. 
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Figure 17 Mo active site region of E. coli PaoABC[158] 
 
Crystallographic data revealed that PaoABC contains a wide, shallow groove with 
short loops at the active site (Figure 17). This structure placed the Moco near the 
surface of the protein and exposed to solvent; a significant structural difference to other 
XO enzymes, which have the Moco situated at the base of a narrower binding pocket. 
The broader binding pocket and lack of channel-lining aromatic residues could explain 
PaoABC’s broad spectrum of substrate activity. PaoABC has recently been utilised in a 
one-pot biocascade for the bioconversion of HMF 18 to the key platform chemical 
replacement FDCA 26 (Scheme 43).[170]  
 
 
Scheme 43 Dual enzyme one-pot cascade for bioconversion of HMF to FDCA 
McKenna et al. were able to produce the bioplastic precursor in an isolated yield 
of ~75 % using PaoABC and an engineered galactose oxidase. In addition, they 
demonstrated application of the cascade on a range of aliphatic and aromatic alcohols to 
give the corresponding carboxylic acids in excellent conversions. 
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1.7. Protein engineering of xanthine oxidases 
 
Molybdo-flavoenzymes (MFE) XOR and AO share some common substrates, but 
initially only the mechanism of XOR had been described in detail.[171] Mammalian 
aldehyde oxidase had been previously expressed in E. coli, however low catalytic 
activity of purified proteins relating to low Moco concentrations remained a 
problem.[172] In order to study the mechanism and biochemical functions of mammalian 
AO (AOX1), Leimkühler et al. developed an expression system for an isoform of 
mouse aldehyde oxidase (mAOX1).[173] Purified recombinant protein from TP1000 E. 
coli cells containing a mobAB knockout (required for MCD assembly) displayed 
activity comparable to the enzyme isolated from mouse liver. Engineered protein 
variants indicated positions Glu1265, Val806 and Met884 were crucial to aldehyde 
oxidase activity. Val806 and Met884 were determined to be responsible for substrate 
stabilisation while Glu1265 played the central role in the mechanism as previously 
discussed (Scheme 44) (1.6.1.). 
 
 
Scheme 44 Key residues in mAOX1 
 
A triple variant E1265Q/V806E/M884R interestingly displayed complete loss of 
aldehyde activity, while just altering positions Val806 and Met884 drastically reduced 
aldehyde activity.  
Previously, Leimkühler’s group had also developed an efficient system for the 
recombinant E. coli expression of a xanthine dehydrogenase from R. capsulatus.[174]  
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Figure 18 Crystal structure of xanthine-bound Rc XDH interacting residues[175] 
 
They later identified the key residues in substrate binding with xanthine in 
equivalent positions as Glu730 Glu232 and Arg310.[175] Mutating these positions to 
match the residues present in mAOX1 (E232V/R310M) yielded a XDH protein devoid 
of purine activity while also displaying a greater specificity for aldehydes. 
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1.8. Project Aims 
 
Molybdenum-containing enzymes of the xanthine oxidase family catalyse the 
oxidative hydroxylation of a broad range of aldehydes and aromatic heterocycles. Their 
use in synthesis until recently has been relatively unexplored; instead literature focusing 
on enzymatic structural characterisation and roles in metabolism of xenobiotics have 
been prevalent. Emerging examples of application have shown the potential for green 
synthesis of carboxylic acids and amides using enzymatic cascades. Many molybdenum 
hydroxylase enzymes utilise naturally abundant oxygen and water as co-substrates 
under ambient conditions and do not require diffusible redox cofactors. In addition, 
mutagenesis of the molybdoenzyme xanthine dehydrogenase from Rhodobacter 
capsulatus has shown that changes in substrate specificity are possible. 
 
Following success in preliminary studies, this work aims to: 
• Further investigate cyclic amide forming reactions using single step 
imine/iminium oxidations with molybdenum-containing oxidoreductases. 
• Examine chemoselectivity with substrates containing multiple sites of oxidation. 
• Employ an engineered monoamine oxidase variant with a commercially 
available xanthine dehydrogenase in a novel amine to amide oxidative cascade. 
• Investigate protein engineering of an aldehyde oxidase through random and 
saturation mutagenesis to modulate substrate specificity toward imine oxidation. 
• Develop a solid-phase activity assay to screen a library of randomly generated 
mutants. 
 
In an analogous approach to the work of Leimkühler, an E. coli periplasmic 
aldehyde oxidase (PaoABC) will be the primary candidate for protein engineering with 
the ultimate goal of producing a robust enzyme for imine to amide biotransformations. 
PaoABC is oxygen dependent, highly robust and amenable to heterologous expression 
in E. coli. 
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Results and Discussion 
 
Chapter 2 
2.0 Biooxidation of cyclic amines and imines to lactams 
 
2.1. Introduction 
 
Amides are structures found in many organic molecules including 
pharmaceuticals[176,177] (penicillin, paracetamol) and polymers[178] (Nylon, Kevlar®). 
The current world population is estimated to be at 7 billion, and with numbers expected 
to exceed 12 billion by the year 2100 demand for amide-containing goods will only 
increase.[179] Synthesis has traditionally involved the use of activating agents to combat 
the poor kinetics of amide formation from its parent molecules. [180,181] This has 
presented several problems including toxicity and poor atom economy; as a result there 
are tonnes of waste produced every year, particularly in the pharmaceutical and fine 
chemical sectors. These obstacles have been formally recognized and atom efficient 
amide synthesis was regarded as the top challenge for organic chemistry in 2007 by the 
ACS Green Chemistry Institute®.[182]  
The need for more sustainable methods has driven much research with some 
success. Notable chemical methods for amide formation include the use of boronic 
acids[183], N-heterocyclic carbenes[184-186], Pd[89], Cu/Ag[90], Ru[91] and gold 
nanoparticles.[93] These chemo-catalytic methods, while having good atom economy, 
also have shortcomings including the requirement for organic solvents, high 
temperature and pressure and expensive and non-renewable catalysts. These methods 
hamper industrial scale-up, and more sustainable green methods of amide synthesis are 
needed.  
The synthesis of amides from amines via an imine intermediate is rare in the 
literature and uses harsh conditions (i.e. m-CPBA).[187] Engineered monoamine oxidase 
(MAO) enzymes reported by Turner et al. have displayed a spectrum of activity for 
amine oxidation.[145,146] Additionally, molybdenum hydroxylases have been documented 
to oxidise a number of imine containing compounds.[161,162] Whilst mammalian AO 
benefits from having broad substrate specificity, attempts to express the fully active 
enzyme in E.coli have had limited success, limiting the availability of purified AO.[172] 
Conversely, R. capsulatus XDH can be expressed in E. coli with little difficulty and can 
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undergo mutagenesis to change its substrate specificity. This has been successful with 
AO type activity found for XDH E232V and XDH E232V / R310M variants compared 
to the wild type as reported by Leimkühler et al.[173]  
A commercial source of E. coli XDH (Sigma-Aldrich) has become available. Ec 
XDH uses oxygen as a terminal electron acceptor, producing H2O2. Ec XDH is 
marketed as “xanthine oxidase microbial”, however it is referred to as a dehydrogenase 
here as it will accept NAD+ as a cofactor. Oxidases have a clear advantage over 
dehydrogenases in that molecular oxygen is used as the oxidant. Unfortunately, the 
crystal structure for Ec XDH is unknown but homologue Rc XDH E232V is believed to 
interact with purines through active site-flanking phenylalanines in the substrate 
channel.[188] Aromatic π-π interactions between phenylalanine and DHIQ could stabilise 
the transition state and lower activation energy. 
XOR enzymes used alone or in combination with MAO hold great potential as 
biocatalysts for oxidative formation of amides. As outlined in the oxidative cascade 
below, an amine 188 could be selectively oxidised to the imine 189, which is then a 
substrate for XOR to produce the corresponding amide 190 (Scheme 45).  
  
 
Scheme 45 Tandem biocatalytic approach to amide formation 
 
This work aims to facilitate the atom efficient conversion of amines to amides 
using such a biocatalytic approach. A MAO variant and XDH will be utilised to 
demonstrate proof of concept. Additionally, single step biooxidations of cyclic 
imine/iminium substrates will be investigated and compared to chemical methods. The 
R1 N
R2
Imine
XOR/XOR mutant
R1 NH
R2
O
Amide
R1 NH
R2
Amine
MAO-N
O2
H2O2
H2O H2O2
Catalase 0.5 O2 + H2O
188
189 190
Results and Discussion  Chapter 2 | 
 
 56 
chemoselectivity of molybdenum hydroxylases on imine-containing substrates with 
multiple sites of oxidation will also be assessed.  
Imines/iminiums formed through cascades in this project were generated in situ 
using an engineered monoamine oxidase, MAO-N D9 provided by our collaborator 
Nick Turner (Manchester, UK). Cascades and single-step imine oxidations were 
facilitated by Rc XDH E232V and Ec PaoABC provided by our other collaborator Silke 
Leimkühler (Potsdam, GER). Initial reactions on the project performed by Dr Carnell 
had some success with the formation of lactams from tetrahydroisoquinolines (THIQs) 
(Scheme 46), where a one-pot enzyme cascade with MAO-N D9 and XDH E232V 
formed the lactam in reasonable yield.[189]  
In this case, the XDH E232V oxidation was facilitated by 2,6-
dichlorophenolindophenol (DCPIP) 195, which is a redox mediator and 1 or 0.5 eq. of 
K3Fe(CN)6 acting as a terminal electron acceptor. Rc XDH E232V is a NAD+ utilising 
enzyme. Using catalytic quantities, the co-factor can in principle be regenerated using 
NADH oxidase.[190] However, the combination of catalytic DCPIP (10 mol%) and 
K3Fe(CN)6 (due to the low aqueous solubility of DCPIP) as electron acceptors worked 
well. 
 
 
Scheme 46 Initial THIQ cascades[189] 
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2.1.1. Monitoring reaction conversions by HPLC 
 
Reaction conversions for enzyme biotransformations were monitored by HPLC. 
Transformations were verified by comparing the retention times observed with samples 
of authentic standards of starting materials and products under the same conditions. 
Where standards were not commercially available, they were synthesised. In order to 
confirm that the relative intensities observed on HPLC traces were indicative of the 
amounts present, 1:1 standards (by NMR analysis) of the lactam and amine were 
analysed by HPLC (section 5.3.5.). Transformations where an intermediate iminium ion 
was formed such as substrate 201 (Table 4) were treated with a reducing agent prior to 
analysis to ensure no substrate remained in the aqueous phase. 
 
2.2. Initial biotransformation of DHIQ with XORs 
 
We initially focused on the biotransformations of 3,4-dihydroisoquinoline (DHIQ) 
197 using both E. coli XDH and Rc XDH E232V. Ec XDH is commercially available, 
while sources of MAO-N D9 were comparatively limited. The E. coli mob locus is 
required for synthesising active molybdenum co-factor molybdopterin-guanine-
dinucleotide (MGD) in molybdoenzymes. XOR enzymes possess the cytosine analogue 
(MCD), and thus require a modified strain of E. coli to heterologously express active 
protein. Palmer et al. developed a TP1000 strain of E. coli with a kanamycin resistance 
cassette and a mobAB knockout resulting in MCD assembly.[191] To avoid continuous 
expression and purification of enzyme by our collaborators, initial trials were run for the 
imine to amide stage of oxidation. Whole cell trials (growing and resuspended) were 
probed using  whole cells (E.coli TP1000) expressing XDH E232V. DHIQ was added 
directly to the growing and re-suspended cells and incubated for three hours at 37 °C. 
The amide was observed from NMR analysis of the crude product. However, difficulty 
in product purification precluded determination of an accurate conversion or product 
isolation.  
 
Scheme 47 DHIQ oxidation using isolated enzymes 
N NH
O197 193
(a) Ec XDH
KPi (50mM p.H 7.6), 
O2, 37 °C, 2 hrs
 (b) Rc XDH E232V
KPi (50mM p.H 7.6), 
10 mol% DCPIP, K3Fe(CN)6, 
20ºC, 2 hrs
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Using the isolated enzymes proved to be more successful. Bioconversion 
reactions using isolated Rc XDH E232V (with DCPIP-K3Fe(CN)6) or commercially 
available Ec XDH (with O2) were performed in potassium phosphate buffer (50 mM, 
pH 7.6) with DHIQ 197  (final substrate concentration of 1 mM). The redox dye DCPIP 
characteristically decolourised upon reduction indicating enzyme activity. The Ec XDH 
biotransformation was followed by normal phase HPLC and showed full conversion to 
the product after 3 h. Efforts to scale up the reaction to 10 and 50 mM substrate 
concentration were less effective with much less of the product observed (24 % and 5 % 
respectively) this was thought to be due to substrate / product inhibition at larger 
concentrations.  
HPLC analysis of Ec XDH reactions required an authentic chemical standard of 
the lactam 193 for comparison. The standard was not commercially available so was 
synthesised by conventional acid chloride coupling to give the carbamate ester 200 
followed by acid catalysed cyclisation as described by Kurouchi et al.[192]  
 
 
Scheme 48 Chemical route to lactam 193[192] 
 
2.3. MAO-N D9 & Ec XDH / Rc XDH E232V cascades 
 
Following the successful biotransformation of DHIQ using Ec XDH, an enzyme 
cascade using MAO-N D9 and Ec XDH with the substrate 1,2,3,4-
tetrahydroisoquinoline (THIQ) 191 was next examined at 1 mM (Table 1 entry 1). 
HPLC analysis showed quantitative conversion to the lactam. The substrate 
concentration was increased to 10 mM (entries 2-4), which still showed moderate 
amounts of conversion. For substrate concentrations of 30 mM (entries 5-7) and 50 mM 
(entries 8-10) conversions were comparatively poor. 
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Table 1 Oxidative cascades of THIQ using MAO-N D9 and Ec XDHa 
 
Entry Molarity (mM) Time (h) Conversion (%) 
1 1 5 100 
2 10 1 39 
3 " 3 30 
4 " 5 34 
5 30 1 13 
6 " 3 11 
7 " 5 10 
8 50 1 7 
9 " 3 9 
10 " 5 7 
aReaction conditions: Incubated at 37 °C with agitation at 180 RPM. Potassium phosphate buffer (50 
mM, pH 7.6), total volume 1000 µL. 10, 30 & 50 µL 191 (in DMF), 50 µL MAO-N D9 (14 mg/ml) and 
100 µL Ec XDH (1 mg/ml). HPLC Conditions: Diacel OJ-H column, 1 ml/min, 10 % IPA/Hexane at 230 
nm. (") signifies a repeat of the above value in a given column. 
 
Reduced conversion at lower substrate concentrations was thought to be due to 
deactivation of the enzyme by the hydrogen peroxide formed during the reaction. 
Continuing with 10 mM 191, a series of biotransformation cascades were run using 
catalase as a peroxide scavenger. 
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Table 2 Catalase supplemented oxidative cascades of THIQ using MAO-N D9 and Ec XDHa 
 
Entry Molarity 
(mM) 
Catalase conc. 
(mg ml-1) 
Time (h) Conversion 
(%) 
1 10 1.1 2 90 
2 " " 4 96 
3 " " 7 97 
4 " 0.55 2 50 
5 " " 4 64 
6 " " 6 67 
7b " 1.1 6 30 
8 20 " 2 22 
9 " " 4 23 
10 " " 6 28 
aReaction conditions: Incubated at 37 °C with agitation at 180 RPM. Potassium phosphate buffer (50 
mM, pH 7.6), total volume 1000 µL. 10 & 20 µL 191 (1 M in DMF), 50 µL MAO-N D9 (14 mg/ml), 100 
µL Ec XDH (1 mg/ml) and catalase 333 or 167 µL (3.3 mg/ml). HPLC Conditions: Diacel OJ-H column, 
1 ml/min, 10 % IPA/Hexane at 230 nm. bNo aeration. (") signifies a repeat of the above value in a given 
column. 
 
The observed conversions (Table 2) indicated that both substrate inhibition and 
peroxide inactivation were playing a role in lower conversions. Catalase provided near 
quantitative conversions by 4 h at 10 mM THIQ concentration. Increasing substrate 
concentration to 20 mM resulted in a significant drop in conversion. Additionally, 
lowering the concentration of catalase by half had a deleterious effect on conversion of 
10 mM THIQ. 
The necessity for regular aeration is demonstrated in these transformations, where 
despite the addition of catalase, lack of aeration led to lower conversion (Table 2 entry 
7). To ensure high degrees of atmospheric oxygen saturation, Eppendorf tube reaction 
vessels were exposed to air then manually shaken for a few seconds every 30 min. 
 
Table 3 Peroxide scavenger screens on 10 mM THIQ MAO-N D9 and Ec XDH cascadea 
NH
MAO-N D9
Ec XDH
Catalase
KPi (50mM p.H 7.6)
O2, 37 °C
NH
O191 193
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Additive Conversion to lactam 
Control 2.5 % 
Catalase 55.2 % 
Superoxide Dismutase 5.6 % 
Peroxidase 26.1 % 
aReaction conditions: Incubated at 37 °C with agitation at 180 RPM. Potassium phosphate buffer (50 
mM, pH 7.6), total volume 1000 µL. 10 µL 186 (1 M in DMF), 50 µL MAO-N D9 (14 mg/ml), 100 µL 
Ec XDH (1 mg/ml) and additive 167 µL (3.3 mg/ml). HPLC Conditions Diacel OJ-H column, 1 ml/min, 
10 % IPA/Hexane at 230 nm. 
 
Two additional peroxide scavengers, peroxidase and superoxide dismutase were 
assayed for improved activity with 191 (10 mM) in place of catalase. Assays were run 
at the same concentration and conditions with catalase remaining the most effective.  
Catalase was then utilised in a series of THIQ analogue cascades using MAO-N 
D9 and Ec XDH (Table 4) or Rc XDH E232V (Table 5). The results obtained using 
THIQ (Table 2 entries 1-4) and N-methyl THIQ 201 (Table 4 entries 5-8) were 
published as part of a so-called “catalytic toolbox” where a series of water-based bio-
chemo and bio-bio cascades contributed towards the green synthesis of carboxylic acids 
/ amides from alcohols and lactams from cyclic amines.[189]   
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Table 4 Cascade biooxidation of THIQ analogues with MAO-N D9 and Ec XDHa 
 
Entry Substrate Molarity 
(mM) 
Time (h) Conversion 
(%)b 
  1c,d 192 1 5 0 
 2d " 10 2 " 
 3d " " 4 " 
 4d " " 6 " 
   5c,d 201 1 6 91 
 6d " 10 2 64 
 7d " " 4 82 
 8d " " 6 100 
9 202 1 " 0 
aReaction conditions: Incubated at 37 °C with agitation at 180 RPM. Potassium phosphate buffer (50 
mM, pH 7.6), total volume 300 µL. 0.3 & 3 µL 192, 201 and 202 (1M in DMF), 17 µL MAO-N D9 (14 
mg/ml), 33 µL Ec XDH or (1 mg/ml) and catalase 100 µL (3.3 mg/ml). HPLC Conditions Diacel OJ-H 
column, 1 ml/min, 10 % IPA/Hexane at 230 nm. bConversion calculated from peak areas of HPLC 
analysis using authentic standards of the amine:lactam in a 1:1 ratio by NMR (Section 5.3.5.). cAbsence 
of catalase. dBefore extraction, the reaction was shaken with ammonia borane complex for 3 hours. (") 
signifies a repeat of the above value in a given column. 
 
Unfortunately substrates 192 and 202 appeared to display no conversion with E. 
coli XDH. N-methyl THIQ 201, on the other hand showed excellent conversions over 6 
h at both 1 and 10 mM (Table 4 entries 5-8). For N-methyl THIQ 201 conversions, the 
lactam showed greater absorbance intensity than was actually present (approx. eight 
fold, section 5.3.5.). Accordingly, the conversions (Tables 4 and 5) have been 
normalised to reflect this. Additionally N-substituted analogues 192 and 201 were 
shaken with ammonia-borane complex to reduce any unconverted iminium, as it would 
partition into the aqueous layer during extraction and give unrepresentative results. 
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Table 5 Cascade biooxidation of THIQ analogues with MAO-N D9 and Rc XDH E232Va,b 
 
Entry Substrate Molarity 
(mM) 
Time (h) Conversion 
(%)c 
 1d 192 1 6 0 
 2e " " " " 
 3f " " " " 
 4e 201 " " 97 
 5f " " " 32 
aReaction conditions: Incubated at 37 °C with agitation at 180 RPM. Potassium phosphate buffer (50 
mM, pH 7.6), total volume 300 µL. 0.3 & 3 µL 192 and 201 (1 M in DMF), 17 µL MAO-N D9 (14 
mg/ml), 33 µL Rc XDH E232V (1 mg/ml) DCPIP 30 µL (10 mM) and catalase 100 µL (3.3 mg/ml). 
HPLC Conditions Diacel OJ-H column, 1 ml/min, 10 % IPA/Hexane at 230 nm.  bBefore extraction, the 
reaction was shaken with ammonia borane complex for 3 hours. cConversion calculated from peak areas 
of HPLC analysis using authentic standards of the amine:lactam in a 1:1 ratio by NMR (see 
experimental). dAbsence of catalase. e10 mol % K3Fe(CN)6. flaccase 1.5 U. (") signifies a repeat of the 
above value in a given column. 
 
 
Rc XDH E232V was examined with substrates 192 and 201 at 1 mM. Laccase 
was also tested as a biological alternative to iron ferricyanide as an electron sink. 
Substrate 192 continued to display no activity with Rc XDH E232V, while 201 had 
greater conversion with iron ferricyanide compared to laccase (Table 5 entries 4-5). 
Interestingly the lack of 192 oxidation is in contrast to a working bio-chemocatalytic 
approach using MAO-N D9 and H2O2/CuI.[189] This could suggest that the presence of 
the nitro group in the 6-position of THIQ was interfering with substrate oxidation in Ec 
XDH / Rc XDH E232V through either steric repulsion in the substrate channel or the 
electron withdrawing nature of the para-nitro group sufficiently deactivated the 
oxidation by reduction of conjugation in the imine intermediate. 
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2.3.1. Synthesis of N-methyl THIQ standards 
 
In order to confirm the biotransformation products for substrate 201 (Table 4 / 5), 
comparison to authentic chemical standards were made using HPLC. The starting 
material 201 was synthesised by methylation and subsequent reduction of the resulting 
DHIQ iminium iodide salt 205.[193,194] 
 
 
Scheme 49 Synthesis of N-methyl THIQ[193,194] 
 
The iminium intermediate 205 was also used to synthesise the lactam standard 
203.[195] 
 
 
Scheme 50 Synthesis of N-methyl THIQ lactam[195] 
 
The requirement of HCl for the oxidation to occur is thought to be due to 
oxysulfonium intermediate, which, upon protonation, cannot undergo the reverse 
transformation due to the unavailability of the nitrogen electron pair. O-S bond cleavage 
followed by deprotonation (or vice-versa) yields the lactam. 
2.4. pH-dependence of biotransformations by Ec XDH 
 
The work that ensued examined the dependence of solvent pH on degree of 
conversion. Beedham et al.[162] first reported that imine substrates required basic media 
to observe activity with  xanthine oxidase. This was also supported by Kitamura et 
al.[155], who reported that XOR enzymes in general appeared to function most efficiently 
at more basic pH (9-10).  
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Table 6 THIQ analogue bioconversion dependence on pHa 
 
Entry Substrate Conversion pH 7 
(%)d 
Conversion pH 8 
(%)d 
 1b 201 82  100  
 2c 206 100  "  
 3c 207 75  " 
 4c 208 86 " 
aReaction conditions: Incubated at 37 °C with agitation at 180 RPM for 16 h. Potassium phosphate buffer 
(100 mM, pH 7 or 8), total volume 300 µL. 3 µL 201 and 206-208 (1 M in DMF), 100 µL catalase (3.3 
mg/ml). b17 µL MAO-N D9 (14 mg/ml), 33 µL Ec XDH (1 mg/ml) and c 33 µL Ec XDH (1 mg/ml). 
HPLC Conditions Diacel OJ-H column, 1 ml/min, 10 % IPA/Hexane at 230 nm. dConversion calculated 
from peak areas of HPLC analysis using authentic standards of the amine:lactam in a 1:1 ratio by NMR 
(see experimental). (") signifies a repeat of the above value in a given column. 
 
Prior transformations had been run at pH 7.6 so pH 7 and 8 as the closest integers 
were selected to examine the effect of small changes in pH on conversion. Comparing 
the cascade of 201 and single step oxidations of 206-208 at pH 7 and 8 overnight 
revealed higher conversion at more basic pH, supporting what had been reported 
previously. We observed that the hydroxyl-containing pseudobase 206 was also fully 
converted at lower pH. A shorter reaction time may provide a better comparison of the 
effect of pH on conversion for faster acting substrates. Beedham stipulated that the 
formation of lactams from nicotine and azapetine proceeded through pseudobase 
intermediates.[162] Having observed improved conversions in slightly basic media, pH 8 
buffer was used on additional imine containing substrates going forward. 
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2.4.1. Synthesis of standards for pH dependence study 
 
A publication by Leonard et al. in the late 1940s outlined a relatively mild method 
for the synthesis of the pseudobase 206 involving washing and filtering the iodide salt 
205 with water followed by the addition of aqueous sodium hydroxide, further filtration 
and extraction into ether.[196] 
 
Scheme 51 Initial unsuccessful attempt at forming the pseudobase[196] and the successful 
method from Hanquet et al.[197] 
 
This was unsuccessful when attempted; the process was designed for an industrial 
scale and the many filtrations on a small scale resulted in a mixture, which could not be 
separated. A similar method utilising a biphasic reaction mixture has been outlined by 
Hanquet et al.[197] This method was adapted, using deuterated dichloromethane to allow 
analysis of the reaction mixture directly following separation of the organic layer. NMR 
analysis showed complete conversion.  
 
 
Scheme 52 Synthesis of quinolinium substrate, dibenzo[b,f][1,4]oxazepine and bicyclic lactam 
standards[193,195,198,199] 
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In analogous methods to that which were used to prepare THIQ N-Me iodide salt 
and lactam by Gray et al.[193] and Ruchiwarat et al.[195], the quinoline salt 207 and 
lactam 212 were successfully made in 61 % and 25 % yield respectively. Interestingly, 
biocatalytic conversions of 207 and 208 to 209 and 210 respectively (Table 6) were 
much greater than the corresponding chemical methods used to produce the authentic 
standards (Scheme 52). Jorapour et al.[198] described a method of forming oxazepine 
type compounds using polyethylene glycol. This was used to access 
dibenzo[b,f][1,4]oxazepine 208 and an oxidation described by Brewster et al.[199] was 
employed to produce the corresponding lactam 210 proceeding in comparatively poorer 
yield (Scheme 52) . 
2.5. Additional bicyclic imine analogues 
 
Selectivity at multiple sites for imine oxidation was initially assessed using 10 
mM quinoxaline 215 and Ec XDH where the mono oxidised product 216 was observed 
(Scheme 53). 
 
Scheme 53 Ec XDH quinoxaline oxidation 
 
Initially believed to be the observed product, the di amide 217, derived from 
quinoxaline 215 was not commercially available and therefore synthesised following a 
procedure by Troian-Gautier et al. (Scheme 54).[200] 
 
Scheme 54 Quinoxaline di amide forming oxidation[200] 
 
An additional group of bicyclic imines (211, 218 and 219) were screened using a 
series of XOR enzymes (PaoABC mutants for entries 5 & 6 will be introduced in 
Chapter 4) to investigate the chemoselectivity in the presence of multiple imine sites 
(Table 7). 
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 Table 7 Bicyclic imine screen with XORs at pH8a 
 
Entry Enzyme 211    
Conversionb  (%) 
218  
Conversionb (%) 
219  
Conversionb (%) 
1 Ec XDH 58 (2-OH) 100 (di) 100 
2 Ec PaoABC 0 100 (mono) 0 
3 Bovine XO " 100 (di) 100 
4 Rc XDH E232V  75 (2-OH) 74 (mono) 0 
5 Ec PaoABC L246E 0 0 " 
6 Ec PaoABC T318R " 67 (mono) " 
aReaction conditions: Incubated at 37 °C with agitation at 250 RPM for 16 h. Potassium phosphate buffer 
(100 mM, pH 8), total volume 1000 µL. 10 µL 211, 218 and 219 (1 M in DMF), 100 µL XOR (1 mg/ml) 
and catalase 100 µL (3.3 mg/ml). bReaction centrifuged (5000 RPM, 1 min) and filtered before 
monitoring conversion by NMR (appendix). (") signifies a repeat of the above value in a given column 
Due to the poor solubility of the products, transformations were monitored via 
NMR (DMSO-d6). Ec PaoABC displayed a preference for mono oxidation of 
quinazoline 218; this preference was shared by Rc XDH E232V and Ec PaoABC 
mutant T318R with partial conversions (no di amide was observed) while L246E 
switched off activity. Conversely, Ec XDH and Bovine XO fully converted quinazoline 
218 to the diamide. This was confirmed by separately assaying the mono amide 219. 
Quinoline 211 was oxidised by both Ec XDH and Rc XDH E232V to give lactam 212 
rather than the oxidation in the 4-position. 
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The same XOR enzymes employed in Table 7 were used to assay another group 
of substrates under the same conditions (Scheme 55).  
 
Scheme 55 Unsuccessful XOR substrate screen 
 
Control reactions for substrates 221 and 222 revealed that they underwent auto-
oxidation under reaction conditions. 5-membered ring-containing substrates 224 and 
226 also displayed no conversion. 
 
2.6. Conclusion 
 
In summary we have developed a novel two-step enzymatic cascade for the 
formation of lactams from cyclic amines in a one-pot reaction. Biocatalytic formation of 
amides is inherently green and has the advantage of ease of use and atom efficiency. 
Two oxygen-dependent enzymes, monoamine oxidase-N D9 and Ec xanthine 
dehydrogenase function in water at ambient temperature (25-37 °C) and near neutral 
pH. The cascade has also been demonstrated using an external electron acceptor with 
xanthine dehydrogenase E232V from Rhodobacter. The enzymes have been previously 
utilised in separate processes, MAO-N D9 was used in the de-racemisation of chiral 
amines and an Rc XDH mutant E232V was shown to have increased aldehyde oxidase 
activity, however they have not been previously combined. Similarly Ec XDH, while 
commercially available, has not been previously used in biotransformations.  
Initial limitations to cascade conversions caused by build up of harmful H2O2 
were overcome through the incorporation of catalase to the reaction. The apparent 
reduction in conversion at higher substrate concentration remained a limitation 
however. 
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The imine/iminium oxidation stage has been further investigated using a range of 
molybdenum hydroxylases for chemoselectivity with respect to multiple sites of 
oxidation. Selectivity for mono oxidation was observed in quinoxaline 215 and 
quinazoline 218 where chemical methods of quinoxaline oxidation gave the fully 
oxidised product.  
Changes in conversions of additional cyclic imines from tuning the pH were also 
investigated, which confirmed a preference for slightly basic media. This compared 
favourably to chemocatalytic methods used in synthesis, which required high 
temperature and harsh conditions.  
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Chapter 3 
 
3.0. Random mutagenesis of Ec PaoABC and development of a solid-phase oxidase 
activity assay 
 
3.1. Introduction 
 
Directed evolution is a powerful technique used to access structurally modified 
enzymes, which may impart such properties as increased solvent or temperature 
tolerance, wider substrate range or improved chemo-, regio- or stereoselectivity. epPCR 
is a method of introducing random mutations throughout a defined region of a protein 
sequence that has the advantage of not requiring the crystal structure. There have been 
many successful examples utilising this technique following the work of Francis 
Arnold[72] as discussed previously.  
Our collaborator, Silke Leimkühler reported the isolation of Ec PaoABC, which is 
the first MCD-containing MFE isolated from E. coli.[169] It catalyses the bio-oxidation 
of a wide range of aliphatic and aromatic aldehydes and is thought to play a role in 
mammalian detoxification of xenobiotics, particularly aromatic aldehydes. It is 
extremely robust and can be heterologously over-expressed using bacterial hosts in the 
laboratory, which is vital for effective isolation and mutation studies. Application of Ec 
PaoABC has been demonstrated in the synthesis of a range of carboxylic acids in 
addition to FDCA, a key platform chemical.[170] Successful mutagenesis of 
molybdenum hydroxylases to demonstrate the reliance of the protein mechanism on 
specific amino acid residues had been carried out.[173] In addition, mutagenesis for 
modulation of substrate specificity has been demonstrated previously by 
Leimkühler.[173]  
Many established bioassays such as western blots, can detect the presence of 
various antibodies through a colorimetric reaction. An antibody-coupled peroxidase 
enzyme, upon interaction with hydrogen peroxide, mediates the oxidation of a redox 
dye. Work in the group of our collaborator, Nick Turner used a variation of this process 
to screen for improved mutations of galactose oxidase (GOase).[99] This involved lysing 
a plate containing bacterial colonies on a nitrocellulose membrane, then saturating the 
membrane with a solution containing the dye, a substrate and horseradish peroxidase 
(HRP). Substrate oxidation would generate H2O2 within the bacterial colony, triggering 
HRP mediated oxidation of the dye to a coloured, insoluble product.  
Results and Discussion  Chapter 3 | 
 
 72 
 
3.2. Ec PaoABC random mutagenesis 
 
Through site-directed mutagenesis, Leimkühler’s group shifted the substrate 
specificity of a xanthine dehydrogenase to that of an aldehyde oxidase. We postulated 
that through mutagenesis, it could be possible to alter the specificity of an aldehyde 
oxidase to that of a xanthine dehydrogenase with the aim of producing an imine 
oxidase.  
As discussed previously, Ec PaoABC is a temperature stable, robust, oxygen-
dependent enzyme with a broad substrate range. As it is oxygen dependent, it doesn’t 
require stoichiometric co-factors or recycling systems. It is also easily expressed in host 
organisms such as E.coli and this made it a strong candidate for mutagenesis. Samples 
of isolated Ec PaoABC enzyme and bacterial cultures of TP1000 x Ec PaoABC were 
kindly provided by our collaborator, Silke Leimkühler (Potsdam, GER).  
At the outset, the crystal structure for PaoABC had not been elucidated so we 
aimed to exploit a random mutagenesis approach using epPCR and develop a suitable 
method for screening mutant libraries. Using the sequence data for the Moco-containing 
PaoC subunit, a homology model was assembled using the Phyre2 web portal for 
protein modelling, prediction and analysis to help identify which region of PaoC to 
mutate.[201] The Phyre2 tool compares a submitted sequence against databases of 
characterised protein crystal structures and constructs a homology model of best 
estimation based on similar proteins available on the database at the time. 
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        1 mkfdkpagen pidqlkvvgr phdridgplk ttgtaryaye wheeapnaay gyivgsaiak 
       61 grltaldtda aqkapgvlav itasnagalg kgdkntarll ggptiehyhq aialvvaetf 
      121 eqaraaaslv qahyrrnkga ysladekqav nqppedtpdk nvgdfdgaft saavkidaty 
      181 ttpdqshmam ephasmavwd gnkltlwtsn qmidwcrtdl aktlkvpven vriispyigg 
      241 gfggklflrs dallaalaar avkrpvkvml prpsipnntt hrpatlqhlr igadqsgkit 
      301 aisheswsgn lpggtpetav qqsellyaga nrhtglrlat ldlpegnamr apgeapglma 
      361 leiaidelae kagidpvefr ilndtqvdpa dptrcfsrrq lieclrtgad kfgwkqrnat 
      421 pgqvrdgewl vghgvaagfr nnlleksgar vhleqngtvt vetdmtdigt gsytilaqta 
      481 aemlgvpleq vavhlgdssf pvsagsggqw gantstsgvy aacmklremi asavgfdpeq 
      541 sqfadgkitn gtrsatlhea taggrltaee siefgtlske yqqstfaghf vevgvhsatg 
      601 evrvrrmlav caagrilnpk tarsqvigam tmgmgaalme elavddrlgy fvnhdmagye 
      661 vpvhadipkq eviflddtdp isspmkakgv gelglcgvsa aianavynat girvrdypit 
      721 ldklldklpd vv 
 
 
Figure 19 Top - AA sequence of PaoC subunit. Yellow - region selected for mutation, purple – 
residues involved in substrate binding red – highly conserved residues. Bottom - Phyre2 
generated homology model of Ec PaoABC[201] 
 
 Based on the estimated structure of the model, we selected a region of 
approximately 300 amino acid residues for mutagenesis. The area of sequence selected 
for mutation and the corresponding regions in the PaoC model are highlighted in 
(Figure 19). Key residues Gln211, Phe242 and Gly243 involved in MCD coordination 
and catalytic Glu 692 are highlighted in red, while residues Leu246 and Thr318, 
displayed in purple, were later found to correspond (via structure-based sequence 
alignment) to Glu232 and Arg310 in Rc XDH, known to be important for substrate 
binding. According to the estimated structure of PaoC, the selected area for mutation 
appeared to cover a reasonable range of residues around the active site. Importantly, the 
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essential Glu692 residue was well outside the mutation region, which minimised the 
risk of producing inactive mutants. Ec PaoABC pMN100 with an ampicillin resistance 
gene[169] was isolated and purified from samples of E. coli TP1000[191] x pMN100 
PaoABC provided and used as a template for mutagenesis. 
 A commercially available “Genemorph II” mutagenesis kit from Agilent was 
used for introducing random mutations within the selected region. Primers were 
designed flanking the outsides of the desired mutation region to ensure the all of the 
highlighted region was included (green Figure 20). PCR with the included “Mutazyme 
II” DNA polymerase resulted in amplification of the desired region with random 
mutations. A high rate of mutation (9-16 mutations / kb) was selected by using a lower 
concentration plasmid to be amplified (100 ng). Low concentrations of plasmid result in 
more replication cycles with increased accumulation of errors.  
 
 
Figure 20 Nucleobase and corresponding AA sequence of mutation region of PaoC indicating 
primer sites (green) 
 
The second stage involved annealing the mutated PaoC sequence back to the 
template and amplifying the mutated PCR product in an additional PCR reaction. The 
product contained a library of mutations within the indicated region of PaoC, which was 
then transformed into a cloning strain of ultracompetent cells and selectively grown on 
ampicillin-containing agar plates for plasmid isolation. A random sampling of 10 
Results and Discussion  Chapter 3 | 
 
 75 
colonies was taken out of ~3000 produced and the corresponding plasmids were 
sequenced to evaluate the efficiency of mutagenesis.  
 
Table 8 Mutagenesis sampling results 
Entry Base Mutation AA Mutation Mutation rate  
(mutations / kb) 
1 T806C 
T1050C 
G1104C 
M269T 
R350R Silent 
L368L Silent 
3.75 
2 - - - 
3 T1145C 
T1302C 
L382P 
G434G Silent 
2.5 
4 T678C 
C1307T 
V226V Silent 
A436V 
2.5 
5 G592A 
C1043T 
C1064G 
V198I 
A348V 
A355G 
3.75 
6 T646A 
C873T 
C1263T 
C216S 
I291I Silent 
P421P Silent 
3.75 
7 - - - 
8 - - - 
9 - - - 
10 G1036C 
G1092A 
C1206A 
G346R 
A364A Silent 
I402I Silent 
3.75 
Region of PaoC DNA amplified: 827bp (-) indicates WT sequence detected 
 
Due to the time-consuming nature of culturing sampled colonies and manual 
plasmid isolation, 10 colonies were selected to assess the degree of mutagenesis. Of the 
colonies containing mutations, an average of 2.5 base substitutions and 1 AA 
substitution per kb was determined. This is significantly less than the 9-16 bp claimed 
in the kit instructions, but given the number of silent mutations a rate of 1 AA 
substitution would theoretically result in 6000 potential mutants over a range of 300 
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AAs. 3000 colonies could provide coverage of approximately half the available 
sequence space if the amount of wild type colonies were consistent so the library was 
taken forward for screening. For each screen ~3000 colonies were grown from TP1000 
E. coli transformed with the plasmid library to express the variants generated. 
Mutagenesis could be further improved through using lower template concentration in 
addition to increasing the number of PCR cycles.  
 
3.3. Development of a solid-phase aldehyde oxidase assay 
 
A solid-phase screen for detecting improved mutants of GOase for the 
enantioselective oxidation of a range of 1-phenylethanol analogues was developed by 
Turner.[99] The assay indirectly detects the presence of hydrogen peroxide produced by 
oxidase enzymes through the colour change of a redox dye in the presence of 
peroxidase. 3,3’-diaminobenzidine (DAB) was employed as the redox dye whereupon 
oxidation, a pink colouration would be observed within a bacterial colony through an 
HRP mediated reaction. In order to successfully assay the bacterial colonies, cultures 
were grown on a nitrocellulose membrane before being assayed. 
To effectively express Ec PaoABC on a nitrocellulose membrane, 0.035 mM 
IPTG and 4 mM sodium molybdate per 200 ml of the nutrient agar were determined to 
be the optimal concentrations after several trials. The membrane was then overlaid and 
bacterial culture applied before incubating overnight at 37 °C. Submerging the 
membrane-bound bacterial colonies in liquid N2 (3 x ~3 seconds) sufficiently lysed 
them for screening. Prior to actual screening, membranes were pre-soaked in phosphate 
buffer containing HRP to remove any endogenous peroxide.  
 
 
Scheme 56 Simplified solid-phase screen workflow 
 
Before screening mutant libraries, some trials were conducted using DAB to 
detect the oxidation of benzaldehyde with WT Ec PaoABC. Benzaldehyde was selected 
as a simple aldehyde with known activity.[169] While initial results seemed encouraging, 
the dye was forming an imine adduct (Scheme 57) with benzaldehyde as indicated by 
Culture plated on 
membrane
Liquid N2 lysis
+
Pre-soak in HRP
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the yellow colouration on white filter paper (Figure 21). This was also confirmed by 
NMR. 
 
 
Figure 21 Ec PaoABC benzaldehyde screen using DAB as a dye 
 
This ultimately resulted in DAB being unsuitable for screening. In addition to 
interfering with the substrate, it was unknown if the peroxide was detected as a result 
from oxidation of the substrate, or the imine adduct. Instead an alternative redox dye 4-
chloronapthol (4-CN) was selected for screening (Scheme 58). 
 
 
Scheme 57 Formation of DAB imine adduct 
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Scheme 58 HRP mediated 4-CN solid phase screen 
 
The dye also had the benefit of not auto-oxidizing over extended periods of time 
as DAB does and reacted positively with benzaldehyde (Figure 22). 
  
 
Figure 22 Plates showing Ec PaoABC colonies, 4-chloronapthol (16.8 mM) and HRP (1.4 
mg/ml): left – no substrate, right – 10 mM benzaldehyde 
 
In addition the solid-phase screen could tolerate up to 50 % DMF as a co-solvent 
after pre-soaking in order to fully solubilise the dye and substrate. Additionally, a liquid 
screen was run to check if the 4-CN dye interacted with benzaldehyde in a similar 
fashion to DAB. Unlike DAB the test appeared to show no immediate reaction without 
the addition of isolated Ec PaoABC whereupon an immediate colour change was 
observed (Figure 23). 
PaoABC
R CO2H
O2 H2O2
R CHO
OH
Cl
HRP
H2O2 H2O
Insoluble 
blue precipitate
230
4-Chloronapthol
(4-CN)
Results and Discussion  Chapter 3 | 
 
 79 
 
Figure 23 Liquid screen of 4-CN (16.8 mM) containing benzaldehyde (10 mM) and HRP (1.4 
mg/ml): left - no PaoABC, right – 2 µl PaoABC (16 mg/ml) 
 
With a suitable detection system in place, DHIQ was screened as a model imine 
substrate against the whole mutant library (~3000 colonies) of Ec PaoABC however no 
hits were observed. Following this initial setback it was decided to instead check for 
improved aldehyde oxidase activity among mutants. Initially benzaldehyde was selected 
as a substrate; plates containing the mutant library (~3000 colonies) were screened in 
addition to a plate containing just the WT enzyme as a control. However, this substrate 
underwent rapid oxidation, which made screening for potential improved mutants 
problematic. A more slowly oxidised substrate, phenylacetaldehyde (PAA) had been 
previously trialled in DAB screenings before the dye was revealed to be acting on the 
substrate and was determined to be a more suitable substrate. A faster mutant L443Q 
taking only 40 min to show activity (compared to 1.5 h for the WT) under DAB assay 
conditions was isolated. This mutant was then re-assessed using the new dye (Figure 
24).  
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Figure 24 25 mM PAA 4-CN screen comparing L443Q mutant (left) to WT PaoABC (right) at 
40 min 
 
The isolated mutant was further verified using the new dye system by co-plating 
the WT PaoABC with L443Q and analysing the sequences of 5 sampled colonies, 
which gave fast colour change (Figure 25). 
 
 
Figure 25 Mixed L443Q / WT PaoABC assay using 25 mM PAA at 30 min. 
 
The sequence of all 5 selected samples contained the mutation indicating PaoABC 
L443Q was indeed an improved mutant for the oxidation of PAA and validating the 
plate screen.  
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Figure 26 Active site of Ec PaoABC L443 residue (blue) R440 (red) and E692 (green) from 
published crystal structure Spheres represent the pterin-bound apical Mo=O and hydroxyl 
ligand (red), in addition to the Mo=S (yellow).[158] 
 
Following the publication of the crystal structure of Ec PaoABC, it was revealed 
that L443 was situated reasonably close (7.3 Å) to the active site.[158] In addition to 
substrate interaction via hydrogen bonding, the mutated residue may also increase 
enzymatic activity through bonding interactions (6.2 Å away) with the key Glu692 
residue. Arg440 was determined to activate Glu692 through charged interactions by 
Leimkühler.[158]  
 
3.3.1. Methods of enzyme purification and characterisation 
 
PaoABC WT and mutants were purified by first obtaining the cell-free extract of 
the mature culture through sonication and centrifugation. The plasmid harbouring the 
PaoABC gene had a polyhistidine-tag fused to the N-terminus of the PaoA sub unit. 
Polyhistidine-tags allow for ease of separation from the cell free extract by HiTrap 
affinity chromatography, where a nickel sepharose resin stationary phase binds to 
histidine, which can then be eluted by displacement using an imidazole gradient. The 
Results and Discussion  Chapter 3 | 
 
 82 
final step involved buffer exchange to remove the imidazole using a de-salting PD-10 
column. 
 
 
Figure 27 Pure PaoABC obtained by affinity chromatography. Lane 1: protein ladder, lane 2: 
flow through, lane 3: wash, lane 4: standard, lane5/6/7: dilution gradient of purified protein. 
The purified protein (WT PaoABC and mutant) was analysed by denaturing 
PAGE, co-running an authentic sample provided by our collaborators. Gels contained 
characteristic bands corresponding to the three sub-units at 85 (Moco), 40 (FAD) and 20 
(Fe-S) kDa. The purified protein could also be pre-identified by a characteristic bronze 
hue afforded by the molybdenum.  
 
3.3.2. Kinetic evaluation of PaoABC L443Q  
 
After observing positive results on the solid phase plate screen, kinetic 
characterisation was performed on isolated PaoABC L443Q vs WT PaoABC for PAA 
oxidation. WT PaoABC and mutants were expressed in E. coli TP1000 cells grown 
using ampicillin selection. Isolated proteins were purified by Hi-Trap nickel affinity 
chromatography as previously discussed. Work in the group of our collaborator Nick 
Turner used a spectrophotometric method to characterise the kinetics of R-selective 
amine oxidases.[202] The adopted method of characterisation here uses a similar 
principle to that of the solid-phase screen by monitoring the formation of H2O2. A dye 
consisting of 4-aminoantipyrene 231 and 2,4,6-tribromo-3-hydroxy-benzoic acid 232 
forms an adduct 233 upon oxidation that remains soluble in aqueous media with an 
absorbance maximum of 510 nm (Scheme 59).  
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Scheme 59 4-aminoantipyrene coupled-enzyme liquid phase assay[202] 
The rate of transformation was spectrophotometrically monitored in a 96 well 
plate assay. Steady state kinetics were calculated by plotting rate (measured in 
triplicate) against substrate concentration (8 values typically between 8 and 0.002 mM) 
and Vmax and Km values extracted using non-linear regression analysis with a fit to the 
Michaelis-Menten equation (Vmax.[S]/Km+[S]).  
 
Table 9 Kinetic parameters of WT PaoABC vs L443Q for PAA oxidationa 
Enzyme	 Km		
(mM)	
Vmax		
(umol	min-1	mg-1)	
kcat		
(min-1)	
kcat/Km		
(min-1	mM-1)	
	 	 	 	 	
WT	 5.4	x	10-2	
(±	1.1	x	10-2)	
1.2	
(±	8.1	x	10-2)	
160	
(±	11)	
2900	
(±	630)	
L443Q	 4.3	x	10-2	
(±	4.8	x	10-3)	
1.3	
(±	4.8	x	10-2)	
180	
(±	6.5)	
4100	
(±	470)	
aReaction conditions: Readings made at 30 °C at 510 nm over 8 min. The rate of production of hydrogen 
peroxide was detected by HRP (microbial, Sigma) and 4-amino antipyrine / 2,4,6-tribromo-3-
hydroxybenzoic acid dye (ε = 29400 L mol-1
 
cm-1). Typically eight different substrate concentrations 
were examined (8 mM down to 0.0015 mM).  
 
Both enzymes exhibited classical Michaelis-Menten kinetics behaviour 
(Appendix). L443Q displayed a modest improvement in Vmax, Km, and kcat, which led to 
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an improvement in substrate specificity for PAA. While the results appear to validate 
the solid-phase screen, the perceived degree of colouration on the plate is greater than 
the improvement in kinetics. 
3.4. Solid-phase assay limitations  
 
3.4.1. Screening mutant library for improved imine oxidase activity 
 
Having discovered an improved aldehyde oxidase mutant PaoABC L443Q, we 
next turned our attention to generating an “imine oxidase”. We therefore didn’t re-
assess the library with PAA using 4-CN as a screen.  
Enzymes for purine oxidation such as XORs are well documented, however 
enzymes for selective imine oxidation would be novel. Shifting the substrate specificity 
from aldehyde to imine is an extremely attractive concept, which would result in a 
biocatalyst geared toward the green synthesis of amides.     
 
 
Scheme 60 Dehydration reactions to form aliphatic imines 
 
A small group of aliphatic imines were synthesised using a simple dehydration 
(Scheme 60) with MgSO4 and molecular sieves. Prior to screening, the substrates were 
analysed by NMR in buffer to determine the ratio of imine to aldehyde (Table 10).   
 
 
Table 10 NMR analysis of aliphatic imines 
Entry Substrate % Aldehyde % Imine 
1 234 50 50 
2 235 18 82 
3 236 5 95 
Substrates were added to 90 % KPi 100 mM pH 8 and 10 % deuterated acetonitrile. Water suppression 
NMR was used to determine the ratio of aldehyde to imine in buffer. 
N ON
OH
N
O
R
NH2 O
H R'
R N R'
MgSO4
Molecular
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DCM, 24 h
235
8 %
234
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Aliphatic imines are known to be unstable in aqueous conditions. It was 
hypothesised that short imines with neighbouring aromatic groups could stabilise the 
imine, however aldehyde was detected in each of the synthesised aliphatic imines. This 
would be problematic during screening as PaoABC would have a clear preference for 
oxidising the aldehyde and the rest of the imine would equilibrate as the aldehyde was 
oxidised. This was confirmed in a liquid phase transformation of 234 with WT PaoABC 
where only the acid and amine were detected (see experimental 5.4.4.).    
 
 
Figure 28 DHIQ - model imine substrate for PaoABC mutagenesis 
 
3,4-dihydroisoquinoline (DHIQ) remains exclusively in the imine form under 
aqueous conditions due to the combined stability of the cyclic structure and conjugation 
with the aromatic system. PaoABC was found to display limited activity with DHIQ 
(Table 11). As can be seen, E. coli XDH is a better catalyst for this substrate  
 
Table 11 Kinetic parameters of WT PaoABC vs Ec XDH for DHIQ 197 oxidationa 
Enzyme	 Km		
(mM)	
Vmax		
(umol	min-1	mg-1)	
kcat		
(min-1)	
kcat/Km		
(min-1	mM-1)	
	 	 	 	 	
PaoABC	 1.6	
(±	0.26)	
9.1	x	10-4	
(±	5.4	x	10-5)	
0.12	
(±	7.3	x	10-3)	
0.08	
(±	0.01)	
E.	coli	XDH	 3.2	
(±	0.41)	
5.5	x	10-2	
(±	3.1	x	10-3)	
7.5	
(±	0.42)	
2.3	
(±	0.33)	
aReaction conditions: Readings made at 30 °C at 510 nm over 24 min. The rate of production of hydrogen 
peroxide was detected by HRP (microbial, Sigma) and 4-amino antipyrine / 2,4,6-tribromo-3-
hydroxybenzoic acid dye (ε = 29400 L mol-1
 
cm-1). Typically eight different substrate concentrations 
were examined (8 mM down to 0.02 mM).  
 
It was reasoned that improving existing activity for a given substrate would be 
much more likely than introducing new substrate specificity. Solid-phase assays on 
membranes expressing the WT PaoABC for a range of DHIQ concentrations (1-25 mM) 
N
197
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displayed no visually observable colour change. These trials were repeated on 
membranes expressing the mutant library but no observable oxidation occurred. It could 
be reasoned that the poor activity of PaoABC for DHIQ could be the limiting factor of 
the plate screen. For PAA, WT PaoABC has a kcat / Km of ~2900, this still required over 
an hour to observe a colour change in the assay. It is also unlikely that a single mutant 
at a random position would improve this significantly. Therefore, in order to identify 
mutants with slightly improved DHIQ specificity, a saturation mutagenesis approach 
was taken where mutants could be analysed by the more sensitive spectrophotometric 
method.   
 
3.4.2. Phenylacetaldehyde (PAA) background oxidation 
 
It was found that during the solid-phase screening that benzaldehyde and PAA 
both underwent microbial background oxidation. This was observed on a control plate 
with membrane bound bacterial colonies grown without induction media and 
intentionally not expressing the PaoABC protein. The oxidation was believed to be 
microbial due to the lack of colour change elsewhere on the membrane outside of the 
bacterial colonies. The rapid oxidation of benzaldehyde largely bypassed this having 
any impact on screening. For PAA this background activity took longer than cells 
expressing the WT PaoABC (~3 h vs 1.5 h), and as all mutants would be exposed to this 
oxidation it was determined there would be no bias. Screening for less active mutants of 
PaoABC on a given aldehyde may be obstructed using this method however.  
A small but consistent amount of background absorbance was detected during 
liquid phase kinetic screening of WT PaoABC vs L443Q on the oxidation of PAA. This 
was overcome by manually correcting the absorbance values by subtracting absorbance 
values of control runs with no PaoABC present. This was done before calculating the 
kinetic parameters presented (see experimental). DHIQ displayed no background 
oxidation. 
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3.5. Conclusion 
 
A region of the Moco containing PaoC subunit of PaoABC has been successfully 
mutated using a random mutagenesis approach. The region of interest was determined 
using a homology model of PaoC. The region was amplified with a controlled rate of 
mutation using epPCR. Commercial sequencing of randomly sampled colonies 
confirmed successful mutations with a frequency of 2.5 base substitutions per kb of 
template which was lower than the expected rate. In the event of a single AA mutation 
across the region of 300 residues, screening ~3000 colonies could provide a reasonable 
coverage of the theoretical 6000 mutants.    
The mutant L443Q was obtained with an apparent improvement in aldehyde 
oxidase activity; initially identified from an ultimately unsuitable screen, this mutant 
was verified with reproducible results using an alternative screening system. The 
improved mutant was further studied in a kinetic assay and shown to possess a small 
improvement in kinetic properties for the substrate phenylacetaldehyde. L443 lies in 
close proximity to the Moco active site and the mutation from an aliphatic leucine to a 
polar glutamine may result in hydrogen bonding interaction thereby activating the 
carbonyl group in the substrate. 
The solid-phase screen appeared to be unsuitable for aliphatic imines, which are 
prone to aldehyde formation under aqueous conditions. Additionally cyclic imines like 
DHIQ failed to give clear results in the initial solid phase screen of the library. This 
could be due to very low baseline activity of DHIQ with WT PaoABC and the lack of 
improved (or significantly improved) mutants generated in the library for imine 
oxidation.  
In Chapter 4, a saturation mutagenesis approach focusing on key substrate binding 
residues will be pursued with kinetic characterisation of isolated mutants using PAA 
and DHIQ as substrates following publication of the PaoABC crystal structure.   
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Chapter 4 
4.0. Saturation mutagenesis of Ec PaoABC L246 and T318 & kinetic evaluation 
4.1. Introduction 
 
Provided structural data of an enzyme is known, site-directed and saturation 
mutagenesis are effective methods of probing the specific effect of amino acid 
substitutions at a given position. Residues around the active site are most frequently 
targeted as they play roles in substrate binding or intermediate stabilisation. Residues 
like glutamate in xanthine oxidoreductases can also be critical to the catalytic 
mechanism of the enzyme. There are several examples discussed previously of 
successful site-directed mutagenesis approaches, whether in combination with other 
mutagenesis methods (Figure 9) or used at anticipated positions of interest (Scheme 
16). 
PaoABC is an exceptional member of the xanthine oxidase family of 
molybdenum-containing enzymes and has only recently been structurally 
characterised.[158] As such, targeted mutation has been limited to studies directly 
concerning its mechanism.[169] Saturation mutagenesis of this enzyme is also not 
reported in the literature.   
4.2. Ec PaoABC L246 and T318 targeted mutagenesis and kinetic evaluation 
 
Structure-based sequence alignment of Ec PaoABC with Rc XDH, another 
structurally characterised XOR enzyme showed several highly conserved residues 
concerned with Moco binding and catalytic activity (Figure 12). Among the non-
conserved residues are two, known to be involved with substrate binding in Rc XDH, 
E232 and R310. Leimkühler previously reported increased “aldehyde oxidase like” 
activity when substituting these residues with those found in mouse aldehyde oxidase 
(mAOX1) through structural alignment (E232V and R310M).[173] 
Sequence alignment of PaoABC for these substrate interacting residues revealed 
L246 & T318 of PaoC as equivalent positions to E232 & R310 in Rc XDH and V806 & 
M884 in mAOX1. Structurally, Ec PaoABC L246 lies close to Rc XDH E232 while Ec 
PaoABC T318 is comparatively further apart from Rc XDH R310 (Figure 29).  
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Figure 29 Structural overlay of substrate binding residues of Ec PaoABC (red) and Rc XDH 
(blue) using published crystal structures (Ec PaoABC PDB id: 5G5G, Rc XDH PDB id: 
1JRO).[158,175] 
Given the importance of analogous residues in other molybdenum enzymes we 
aimed to mutate these positions and directly analyse the effect of residue substitutions 
on the kinetics. This method bypassed the requirement for a solid phase assay, which 
proved problematic for DHIQ as a substrate. 
 Prior to saturation mutagenesis, we designed primers for site-specific mutations 
L246E, T318R and then made the double mutant L246E/T318R from the L246E 
mutant. Mutations were carried out using the “Quick Change II” mutagenesis kit from 
Agilent. Successful mutants were verified through sequencing of isolated plasmids by 
Eurofins Genomics (Ebersburg, Germany). PCR reactions were initially unsuccessful, 
attempts to remedy this included reducing the template concentrations (higher primer to 
template ratio) and altering the annealing temperature (in case of non-specific binding). 
The inclusion of 3 % DMSO as an additive in PCR reactions ultimately resulted in 
successful mutagenesis based on sequencing. DMSO is often used with GC rich 
sequences to destabilise secondary structure formation, which would otherwise interfere 
with PCR. 
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The single mutants and double mutant were then successfully expressed and 
purified in TP1000 E. coli before kinetic analysis (Table 12). Phenylacetaldehyde 
(PAA) and 3,4-dihydroisoquinoline (DHIQ) remained the substrates for aldehyde and 
imine screening due to existing PaoABC activity and a working procedure for kinetic 
analysis.  
 
Table 12 Kinetic parameters of mutants for PaoABC PAA oxidationa 
Enzyme	 Km		
(mM)	
Vmax		
(umol	min-1	mg-1)	
kcat		
(min-1)	
kcat/Km		
(min-1	mM-1)	
	 	 	 	 	
WT	 5.4	x	10-2	
(±	1.1	x	10-2)	
1.2	
(±	8.1	x	10-2)	
160	
(±	11)	
2900	
(±	630)	
L246E	 n.d.	 n.d.	 n.d.	 n.d.	
T318R	 1.0	x	10-2	
(±	2.3	x	10-3)	
0.22	
(±	5.4	x	10-3)	
31	
(±	0.70)	
3000	
(±	670)	
L246E/T318R	 2.5	
(±	0.30)	
0.66	
(±	5.2	x	10-2)	
90	
(±	7.1)	
37	
(±	5.0)	
aReaction conditions: Readings made at 30 °C at 510 nm over 8 min. The rate of production of hydrogen 
peroxide was detected by HRP (microbial, Sigma) and 4-amino antipyrine / 2,4,6-tribromo-3-
hydroxybenzoic acid dye (ε = 29400 L mol-1
 
cm-1). Typically eight different substrate concentrations 
were examined (8 mM down to 0.0015 mM). n.d. = no absorbance detected 
 
L246E had no detectable PAA activity while T318R lowered kcat but almost 
completely retained PAA specificity. The double mutant had half the Vmax and both Km 
and kcat were negatively affected.  Mutations at these residues were clearly having a 
direct effect on the activity of the enzyme. Kinetic screens of the single and double 
mutants with DHIQ yielded no observable activity, so a saturation mutagenesis 
approach at the two residues was taken.  
4.3. Ec PaoABC saturation mutagenesis 
 
Saturation mutagenesis involves designing primers with degenerate codons at 
positions encoding residues to be mutated. Degenerate codons are designed with a mix 
of potential oligonucleotide combinations at a given position. Depending on the 
combinations of nucleobases employed, all 20 naturally occurring amino acids are 
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potentially available for substitution. Additionally, three termination codons exist 
(TAA, TAG, GTA), which encode for stopping protein synthesis. Adopting a partially 
degenerate codon such as NNK can mitigate the risk of introducing termination codons. 
This approach still allows potential access to all amino acids while reducing the chance 
of getting a termination codon by 3. 
 
Table 13 Degenerate codon table 
Degenerate 
codon 
No. of codons No. of amino 
acids 
No. of stops Amino acids 
encoded 
NNN 64 20 3 All 20 
NNK / NNS 32 20 1 All 20 
NDT 12 12 0 RNDCGHILFSYV 
DBK 18 12 0 ARCGILMFSTWV 
NRT 8 8 0 RNDCGHSY 
 
Zheng et al. developed a variation of saturation mutagenesis using the 
“QuickChange II” Agilent kit.[203] The strategy utilises primers with overlapping 
regions at the codon to be mutated. Primers were designed with overhanging regions 
(blue and yellow Figure 30) at opposite ends to minimise primer self-annealing seen in 
complementary primers. Degenerate primers with NNN containing codons at L246 and 
T318 were used. 
 
 
Figure 30 Template AA sequence of PaoC bold and underlined codons coding for L246 (CTG) 
and T318 (ACG) blue = forward primer, yellow = reverse primer, green = overlapping region, 
red base = controlled silent forward mutation 
 
 As outlined in the method, the primers contained an overhang of at least 8 
residues in each direction in addition to a silent forward mutation to confirm successful 
mutation. The aim was to use this improved method of mutagenesis to efficiently 
generate mutants at L246 and T318. Following the described protocol, a 50 ng scale 
Forward primer
Reverse primer
L246
T318
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mutagenesis PCR reaction was run, transforming the PCR product in XL-10 Gold 
ultracompetent cells. Following incubation the culture was plated onto LB agar 
resulting in no growth for either reaction. Following this, the PCR was attempted again 
using DMSO as an additive and using a greater volume of PCR product to transform. 
This also resulted in no growth. An additional attempt was made, increasing the number 
of cycles in the PCR, the template size (100 ng) and primer conc. (10x i.e. ~1 ug) also 
to no avail. Redesigned overhanging primers with NNKs instead of NNNs were 
explored with little improvement.  
Having had little success with the overhanging strategy for generating a range of 
variants at L246 and T318, an additional kit advertised as more suited to saturation 
mutagenesis, the “Quick Change Multi” site directed mutagenesis kit (Agilent) was 
used. The protocol recommended the use of complementary primers, so primers 
containing NNKs were designed and PCR was run with the inclusion of 5 % DMSO. 
This approach was successful and generated approximately 60 individual colonies in 
total, which were sampled, cultured and purified in order to be identified by sequencing. 
The colonies sequenced contained several silent mutations, termination codons and 
repeats. 4 individual mutants for L246 and 6 for T318 were identified. These combined 
with the site-specific mutations covered multiple amino acid types (Table 13). 
Unfortunately only 25 % of the potentially available mutants were isolated. NNK 
degenerate codons would still have allowed for all 20 potential amino acid substitutions. 
This suggests mutagenesis was successful but there may have been problems with 
transformation efficiency. 
 
Table 14 L246 and T318 mutants 
AA type L246 mutant T318 mutant 
Aliphatic L246G T318G 
- L246V T318P 
- - T318L 
Acidic L246E T318E 
Basic L246H T318R 
Hydroxyl L246S T318S 
Amide - T318N 
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Figure 31 Positions of L246, T318 and key catalytic E692 in PaoABC crystal structure. Spheres 
represent the pterin-bound apical Mo=O and hydroxyl ligand (red), in addition to the Mo=S 
(yellow).[158] 
 
L246 lies close to the Moco (3.5 Å), while T318 is further away (9.9 Å). Site-
directed mutagenesis has demonstrated both positions have an effect on PaoABC 
activity, although whether this is a direct effect or through secondary interactions is 
unknown. Of the novel identified mutants, all were successfully expressed and purified 
except for T318N. Several attempts to express the protein were made with no visual 
indication of molybdenum present during purification (molybdenum containing 
enzymes have a characteristic bronze hue in solution). As the sole example of an amide 
containing mutation it is possible that T318N could have interfered with Moco 
insertion.  
 
4.4. Kinetic evaluation of mutants 
 
The kinetic assay using 4-aminoantipyrene and 2,4,6-tribromo-3-hydroxybenzoic 
acid was further utilised in the characterisation of saturation mutants.  
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4.4.1. PaoABC L246 mutant kinetics for phenylacetaldehyde (PAA) 
 
Table 15 Kinetic parameters of PaoABC L246 saturation mutants for PAA oxidationa 
Mutant	 Km		
(mM)	
Vmax		
(umol	min-1	mg-1)	
kcat		
(min-1)	
kcat/Km		
(min-1	mM-1)	
	 	 	 	 	
WT	PaoABC	 5.4	x	10-2	
(±	1.1	x	10-2)	
1.2	
(±	8.1	x	10-2)	
160	
(±	11)	
290	
(±	630)	
L246G	 5.8	x	10-2	
(±	9.6	x	10-3)	
4.8	x	10-2	
(±	2.1	x	10-3)	
6.6	
(±	0.30)	
110	
(±	19)	
L246V	 5.1	
(±	1.8)	
1.0	
(±	0.27)	
140	
(±	37)	
27	
(±	12)	
L246H	 n.d.	 n.d.	 n.d.	 n.d.	
L246S	 3.2	
(±	0.75)	
0.66	
(±	0.11)	
90	
(±	15)	
29	
(±	8.0)	
aReaction conditions: Readings made at 30 °C at 510 nm over 8 min. The rate of production of hydrogen 
peroxide was detected by HRP (microbial, Sigma) and 4-amino antipyrine / 2,4,6-tribromo-3-
hydroxybenzoic acid dye (ε = 29400 L mol-1
 
cm-1). Typically eight different substrate concentrations 
were examined (8 mM down to 0.0015 mM). n.d. = no absorbance detected 
 
L246H, a charged amino acid substitute was found to have no measurable activity 
with PAA, while each active mutation at L246 lowered the kcat/Km of PaoABC for PAA 
compared to the WT. L246V retained the majority of kcat however this mutation also 
saw a marked increase in Km. A similar outcome was observed for L246S, with a more 
pronounced drop in kcat. L246G, another aliphatic substitution largely retained the Km 
but lost almost all kcat. No mutants had an improved Vmax. 
 
 
 
 
 
 
 
 
 
 
Results and Discussion  Chapter 4 | 
 
 95 
4.4.2. T318 mutant kinetics for phenylacetaldehyde (PAA) 
 
 
Table 16 Kinetic parameters of PaoABC T318 saturation mutants for PAA oxidationa 
Mutant	 Km		
(mM)	
Vmax		
(umol	min-1	mg-1)	
kcat		
(min-1)	
kcat/Km		
(min-1	mM-1)	
	 	 	 	 	
WT	 5.4	x	10-2	
(±	1.1	x	10-2)	
1.2	
(±	8.1	x	10-2)	
160	
(±	11)	
2900	
(±	630)	
T318G	 2.9	x	10-2	
(±	2.4	x	10-3)	
0.20	
(±	2.8	x	10-3)	
27	
(±	0.40)	
930	
(±	78)	
T318P	 2.6	x	10-2	
(±	2.4	x	10-3)	
0.17	
(±	2.6	x	10-3)	
24	
(±	0.40)	
900	
(±	85)	
T318L	 2.5	x	10-2	
(±	7.3	x	10-3)	
0.11	
(±	6.1	x	10-3)	
15	
(±	0.80)	
610	
(±	180)	
T318E	 1.9	x	10-2	
(±	1.4	x	10-3)	
0.19	
(±	2.2	x	10-3)	
15	
(±	0.30)	
610	
(±	180)	
T318S	 1.8	x	10-2	
(±	6.9	x	10-3)	
0.14	
(±	8.7	x	10-3)	
20	
(±	0.30)	
1100	
(±	430)	
aReaction conditions: Readings made at 30 °C at 510 nm over 8 min. The rate of production of hydrogen 
peroxide was detected by HRP (microbial, Sigma) and 4-amino antipyrine / 2,4,6-tribromo-3-
hydroxybenzoic acid dye (ε = 29400 L mol-1
 
cm-1). Typically eight different substrate concentrations 
were examined (8 mM down to 0.0015 mM). 
 
In comparison to L246, T318 mutations had a lesser effect on PAA kcat/Km 
although activity (kcat) was significantly reduced. The lower specificity observed could 
be in relation to the increased distance from the active site compared to L246. The 
hydroxyl moiety in T318 may be playing a significant catalytic role through hydrogen 
bonding, similarly to R440 in E. coli XDH. Interestingly the activity was not retained 
for the similar serine side chain in T318S and no improvement in kcat was observed in 
any of the other mutations at T318. Every mutant displayed a reduction in Km.  
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4.4.3. L246 mutant kinetics for 3,4-dihydroisoquinoline (DHIQ) 
 
Saturation mutants were additionally assayed for DHIQ activity similarly to the 
site-specific mutants to look for a variant with improved imine oxidase activity. 
 
 
Table 17 Kinetic parameters of PaoABC L246 saturation mutants for DHIQ oxidationa 
Mutant	 Km		
(mM)	
Vmax		
(umol	min-1	mg-1)	
kcat		
(min-1)	
kcat/Km		
(min-1	mM-1)	
E.	coli	XDH	 3.2	
(±	0.40)	
5.5	x	10-2	
(±	3.1	x	10-3)	
7.5	
(±	0.40)	
2.3	
(±	0.33)	
	 	 	 	 	
WT	PaoABC	 1.6	
(±	0.26)	
9.1	x	10-4	
(±	5.4	x	10-5)	
0.12	
(±	7.3	x	10-3)	
0.08	
(±	0.01)	
L246G	 0.24	
(±	4.7	x	10-2)	
3.9	x	10-3	
(±	2.9	x	10-4)	
0.54	
(±	3.9	x	10-2)	
2.2	
(±	0.47)	
L246V	 n.d.	 n.d.	 n.d.	 n.d.	
L246E	 n.d.	 n.d.	 n.d.	 n.d.	
L246H	 n.d.	 n.d.	 n.d.	 n.d.	
L246S	 0.22	
(±	3.4	x	10-2)	
1.8	x	10-3	
(±	8.5	x	10-5)	
0.25	
(±	1.2	x	10-2)	
1.1	
(±	0.18)	
aReaction conditions: Readings made at 30 °C at 510 nm over 24 min. The rate of production of hydrogen 
peroxide was detected by HRP (microbial, Sigma) and 4-amino antipyrine / 2,4,6-tribromo-3-
hydroxybenzoic acid dye (ε = 29400 L mol-1
 
cm-1). Typically eight different substrate concentrations 
were examined (8 mM down to 0.02 mM). n.d. = no absorbance detected. 
 
A general observation as previously noted pertains to the rate of DHIQ oxidations. 
The kinetic assay was run for triple the length of time compared with PAA (24 min vs 8 
min). Valine, glutamic acid and histidine substitutions were all inactive, while L246G is 
a very interesting mutant. It has 6 times lower Km, 4 times greater Vmax, 4.5 times faster 
kcat and consequently a 28-fold improvement in specificity for DHIQ. This is 
comparable to Ec XDH and suggests a switch in substrate specificity. Glycine 
substitution at L246 may provide improved steric freedom for DHIQ to bind to the 
active site. There may also be other interactions that leucine was previously obstructing. 
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The other active mutant, L246S has a comparable Km to L246G and improved Vmax, kcat 
and kcat/Km compared to WT PaoABC. 
  
4.4.4. T318 mutant kinetics for 3,4-dihydroisoquinoline (DHIQ) 
 
Table 18 Kinetic parameters of PaoABC T318 saturation mutants for DHIQ oxidationa 
Mutant	 Km		
(mM)	
Vmax		
(umol	min-1	mg-1)	
kcat		
(min-1)	
kcat/Km		
(min-1	mM-1)	
E.	coli	XDH	 3.2	
(±	0.40)	
5.5	x	10-2	
(±	3.1	x	10-3)	
7.5	
(±	0.42)	
2.3	
(±	0.33)	
	 	 	 	 	
WT	 1.6	
(±	0.26)	
9.1	x	10-4	
(±	5.4	x	10-5)	
0.12	
(±	7.3	x	10-3)	
0.08	
(±	0.01)	
T318G	 2.3	
(±	0.35)	
6.9	x	10-4	
(±	3.9	x	10-5)	
0.090	
(±	5.3	x	10-3)	
0.04	
(±	6.5	x	10-3)	
T318P	 3.7	
(±	1.2)	
9.9	x	10-4	
(±	1.5	x	10-4)	
0.13	
(±	2.0	x	10-2)	
0.04	
(±	0.01)	
T318L	 n.d.	 n.d.	 n.d.	 n.d.	
T318E	 2.7	
(±	0.93)	
9.8	x	10-4	
(±	1.8	x	10-5)	
0.13	
(±	2.4	x	10-2)	
0.05	
(±	0.01)	
T318S	 4.1	
(±	0.57)	
9.9	x	10-4	
(±	6.5	x	10-5)	
0.13	
(±	2.1	x	10-2)	
0.03	
(±	5.0	x	10-3)	
aReaction conditions: Readings made at 30 °C at 510 nm over 24 min. The rate of production of hydrogen 
peroxide was detected by HRP (microbial, Sigma) and 4-amino antipyrine / 2,4,6-Tribromo-3-
hydroxybenzoic acid dye (ε = 29400 L mol-1
 
cm-1). Typically eight different substrates concentrations 
were examined (8 mM down to 0.02 mM). n.d. = no absorbance detected. 
 
In contrast to L246 mutants where kinetic values were measured for DHIQ, all 
mutations at T318 had higher Km values and much lower specificity toward DHIQ. All 
mutantations similarly lowered kcat compared to WT PaoABC.  
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4.5 Conclusion 
 
A site-directed mutagenesis method has been used to produce Ec PaoABC 
mutants L246E, T318R and L246E/T318R in an inverse approach to Leimkühler’s 
“XOR to AO” activity mutations. Kinetics revealed a distinct drop in kcat/Km for mutants 
compared with the WT. Unfortunately, the equivalent increase in DHIQ activity was not 
observed in the mutants. This may be in part due to differences in the protein’s substrate 
binding area, particularly with respect to lack of aromatic stabilising residues and tight 
binding channel.[158] Despite the lack of imine activity, the drastic change in kinetics 
suggested L246 and T318 play a significant role in enzyme activity.  
In order to screen a range of substitutions at these positions, a saturation 
mutagenesis approach was undertaken and successfully implemented after a number of 
experimental hurdles were overcome. Examples of aliphatic, acidic, basic and hydroxyl 
amino acid substitutions were introduced at both positions. None of the mutations 
improved substrate specificity for PAA, since variants had reduced kcat and higher Km.  
L246G and L246S, the only mutants active with DHIQ both displayed much less 
substrate specificity for PAA compared with the WT. Our best example, L246G 
exhibited a switch in substrate specificity by having 26-fold less kcat/Km for PAA than 
the WT, while having 28-fold greater kcat/Km for DHIQ compared with the WT. This 
result in particular is exciting, as the specificity is almost that of xanthine 
dehydrogenase. Additionally, the other active mutant L246S obtained suggests potential 
for further improvement of PaoABC for imine oxidation.  
Further work should aim to explore the rest of the potential amino acid 
substitutions at both positions (i.e. aromatic, amide or sulphur containing residues) in 
addition to screening other cyclic amines/imines.  
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Chapter 5 
5. Experimental Section 
5.1. Chemical Experimental 
 
5.1.1. Chemicals 
 
Unless stated otherwise, all reagents were commercially available. Solvents for 
extraction and FCC were technical grade. Reported solvent mixtures for both TLC and 
FCC were volume/volume mixtures. Solvents were analytical or HPLC grade and 
purchased dried over molecular sieves where necessary. 
 
5.1.2. Analytical methods 
 
Analytical thin layer chromatography (TLC) was performed on Whatman F254 
precoated silica gel plates (250 µm thickness). Visualization was accomplished with a 
UV light and/or a KMnO4 solution. Flash column chromatography (FCC) was 
performed using Whatman Silica Gel 60Å (230-400 mesh). Normal and reverse phase 
HPLC was performed on an Agilent system (Santa Clara, CA, USA) equipped with a 
G1379A degasser, G1312A binary pump, a G1329 well plate autosampler unit, a 
G1315B diode array detector and a G1316A temperature controlled column 
compartment. The University of Liverpool analytical services department provided 
Mass spectrometry. 1H NMR and 13C NMR were recorded on Bruker AV 500 MHz & 
Bruker DPX 400 MHz NMR spectrometers in the indicated deuterated solvents. For 1H 
NMR CDCl3 was set to 7.26 ppm (CDCl3 singlet) and for 
13C NMR to 77.66 ppm 
(CDCl3 centre of triplet). All values for 
1H NMR and 13C NMR chemical shifts for 
deuterated solvents were obtained from Cambridge Isotope Labs. Data are reported in 
the following order: chemical shift in ppm (δ), integration,  (multiplicity, which are 
indicated by br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet)) 
and coupling constants (J, Hz).  
 
5.2. General Biology Experimental 
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5.2.1. Enzymes and competent cells 
 
E. coli XDH (sold as xanthine oxidase, microbial), Bovine milk xanthine oxidase, 
catalase and horseradish peroxidase were purchased from Sigma-Aldrich. MAO-N D9 
was kindly provided by Professor N. Turner, Manchester Institute of Biotechnology, 
University of Manchester. PaoABC, XDH E232V and competent E. coli TP1000 cells 
were kindly provided by Professor S. Leimkühler, Institute of Biochemistry and 
Biology, University of Potsdam. The E. coli TP1000 mutant strain used for WT/mutant 
PaoABC and XDH E232V expression is a derivative of MC4100 with a kanamycin 
cassette inserted in the mobAB gene region.[191] Ultracompetent cells used for PaoABC 
mutant cloning include XL 10-Gold and XL 1-Blue, purchased from Agilent 
Technologies and used according to the manufacturers instructions.  
 
5.2.2. DNA and protein methods 
 
5.2.2.1. Plasmids 
 
All PaoABC plasmids were isolated from bacterial cultures using a commercial plasmid 
mini-prep kit (Qiagen). Plasmids for XDH variant E232V (pSL207) and PaoABC 
(pMN100) were provided pre-cloned, using a pTrcHis vector (Invitrogen) with a His6-
tag fused to the N-terminus of XDHA and PaoA subunits for affinity purification. WT 
and mutant PaoABC plasmids in addition to XDH E232V were transformed into E. coli 
TP1000 (ΔmobAB) competent cells. DNA mutagenesis was performed using a Prime 
Gradient thermal cycler (Techne) and PCR products were transformed into cloning 
strains XL 10-Gold or XL 1-Blue ultracompetent cells (Agilent Technologies). Primer 
synthesis for mutagenesis reactions and plasmid sequencing were performed by 
Eurofins Genomics (Ebersburg, Germany).  
 
5.2.2.2. Cultures and protein expression 
 
Bacterial colonies were grown on LB agar (Miller) containing 100 µg / ml ampicillin 
and 50 µg / ml kanamycin at 37 °C for 18 h in a static incubator. Cultures for plasmid 
isolation were prepared from a single colony using 5 ml LB broth (Miller) containing 
100 µg / ml ampicillin and grown for 18 h at 37 °C with shaking at 250 RPM. Starter 
cultures for protein expression were prepared by single colony (TP1000 x PaoABC or 
XDH E232V) inoculation of 50 ml of LB (Miller) containing 100 µg / ml ampicillin, 
supplemented with 1 mM sodium molybdate and 10 µM isopropyl thio-β-D-galactoside 
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(IPTG). Starter cultures were incubated in non-baffled flasks in a static incubator at 37 
°C for 48 h. Main cultures were inoculated using 1 ml of starter culture in 500 ml LB 
(Miller) with 1 mM sodium molybdate and 10 µM IPTG. XDH E232V was grown for 
24 h at 30 °C with shaking at 130 RPM, while PaoABC was grown for 24 h at 22 °C 
with shaking at 120 RPM. Cells were spun down and stored as pellets at -80 °C. 
 
5.2.2.3. Protein purification 
 
Cell pellets were thawed and resuspended in phosphate buffer (0.1 M, pH 7.6) 
containing 300 mM NaCl and 10 mM imidazole. DNase I (1 U / ml lysate) was added 
and cell lysis was performed by sonication (20 s on, 20 s off x20 cycles) using a 
Soniprep 150 plus (MSE UK Ltd.). Cell debris was removed by centrifugation at 17000 
G for 30 minutes. The lysate was loaded onto a HisTrap 1mL FastFlow affinity column 
(GE Healthcare) and the column washed with 10 mL resuspension buffer containing 20 
mM imidazole. The protein was then eluted using 2 ml resuspension buffer containing 
0.3 M imidazole and buffer exchanged into Tris-HCl (50 mM, pH 7.5) containing 1 mM 
ethylenediaminetetraacetic acid (EDTA) using a PD-10 Sephadex column (GE 
Healthcare). Purified protein was quantified spectrophotometrically using a NanoDrop 
Lite (Thermo Fisher Scientific, USA). Purity was analysed by SDS-PAGE using pre-
cast Tris/glycine 4 – 20% Tris-Hepes gel, (NuSep) stained with “Instant Blue” 
(Expedion). 
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5.2.2.4. Kinetics 
 
The initial rates were followed on a TECAN Spark 10M spectrophotometer at 30 °C 
and 510 nm. A 1:1 ratio was assumed in the oxidation of substrate : production of 
hydrogen peroxide. The rate of production of hydrogen peroxide was detected by HRP 
(microbial, Sigma) and 4-amino antipyrine / 2,4,6-tribromo-3-hydroxybenzoic acid dye 
(ε = 29400 L mol-1
 
cm-1). The dye was made up by adding 100 µl 4-amino antipyrine 
(100 mg / mL) and 30 µL (20 mg / mL) 2,4,6-tribromo-3-hydroxybenzoic acid to 10 mL 
of pH 8.0 potassium phosphate buffer. Substrates were dissolved in DMF to 0.5 M then 
diluted in buffer. Typically eight different substrate concentrations were examined (8 
mM down to 0.0015 mM). HRP was dissolved in 0.1 M potassium phosphate buffer, pH 
8.0, to give 1.4 mg / mL concentration. To a 96 well plate 50 µL HRP, 50 µL dye and 
33 µL purified enzyme (typically 0.025 – 1 mg / mL) were added. The assay was started 
by adding 67 µL substrate. Rate was measured in triplicate and plotted against substrate 
concentration and Vmax and KM The kinetic parameters, kcat and KM, were calculated by 
using curve-fitting software Sigma Plot kinetics module (Systat Software Inc.) to fit the 
data to the Michaelis-Menten equation Vmax.[S]/KM+[S]. The errors represent the 95% 
confidence interval of the variance in the fit. 
 
5.2.2.5. PAA background correction 
 
Blank samples for PAA assays were run and background absorbance was removed. This 
allowed for accurate determination of kinetics in improved mutants while correcting 
perceived activity in poor mutants. 
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Figure 32 L443Q background PAA correction 
 
 
 
Figure 33 L246G background PAA correction 
5.3. Chapter 2 Experimental 
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5.3.1. General HPLC 
 
 
Table 18 Imine substrate retention times and conditions 
Entry Substrate Retention Time 
(Min) 
Conditions 
1 
 
5.1 A 
2 
 
5.7 A 
3 
 
9.1 A 
4 
 
5.1 A 
5 
 
8.1 A 
6 
 
9.4 A 
7 
 
5.3 A 
8 
 
11.4 A 
9 
 
12.2 A 
10 
 
9.7 A 
11 
 
4.3 B 
12 
 
2.9 B 
13 
 
2.4 B 
Column conditions – A: Normal phase Diacel OJ-H chiral column, 90:10 hexane:isopropyl 
alcohol, 1 ml/min UV 230 nm. B: Reverse phase Thermo Fischer Scientific C-18 column, 70:30 
deionised water (containing 0.1 % trifluoroacetic acid): Acetonitrile 1 ml/min UV 254 nm. 
N
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NH
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N
N
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N
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N O
N
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5.3.2. General Biotransformation Procedures 
 
General procedure for imine/iminium biotransformations (10 mM) using Rc XDH 
E232V 
 
 
 
To an Eppendorf tube, the substrate in DMF (3 µl, 1 M), potassium ferricyanide (30 µl, 
10 mM), dichloroindophenol (30 µl, 10 mM) xanthine dehydrogenase mutant E232V 
(33 µl, 1 mg/ml) in potassium phosphate buffer (50 mM, pH 7.6) catalase (100 µl, 3.3 
mg/ml, pH 7.6) and potassium phosphate buffer (117 µl, 50 mM, pH 7.6) were added. 
The Eppendorf was then incubated at 37 °C and shaken with extractions taken as 
necessary. The reaction mixture/extracts were extracted with dichloromethane and 
analysed via HPLC on a Diacel OJH chiral column HPLC (conditions: 10% IPA / 
hexane, 1 ml/min at 230 nm). 
 
General procedure for imine/iminium biotransformations (10 mM) using Ec XDH 
 
 
 
To an Eppendorf tube, the substrate in DMF (3 µl, 1 M), Ec XDH (33 µl, 1.1 mg/ml) in 
potassium phosphate buffer (50 mM, pH 7.6), catalase (100 µl, 3 mg/ml, pH 7.6) and 
potassium phosphate buffer (147 µl, 50 mM, pH 7.6) were added. The Eppendorf was 
then incubated for required time at 37 °C and shaken with extractions taken as 
necessary. The reaction mixture/extracts was extracted with dichloromethane and 
analysed via HPLC on a Diacel OJH column (conditions: 10% IPA / hexane, 1 ml/min 
at 230 nm). 
 
 
 
N NH
O197 193
 Rc XDH E232V
KPi (50mM p.H 7.6), 10 mol% DCPIP, 
K3Fe(CN)6, 20ºC, 2 hrs
N NH
O197 193
Ec XDH
KPi (50mM p.H 7.6), 
O2, 37 °C, 2 hrs
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General procedure for MAO-N D9 / Ec XDH cascades (1-10 mM) 
 
 
 
To an Eppendorf tube, the substrate in DMF (3 µl, 1 M), MAO-N D9 (30 µl, 14 mg/ml) 
xanthine oxidase (100 µl, 1.1 mg/ml) in potassium phosphate buffer (50 mM, pH 7.6), 
catalase (100 µl, 3 mg/ml pH 7.6) and potassium phosphate buffer (67 µl, 50 mM, pH 
7.6) were added. The Eppendorf tube was then incubated for the required time at 37 °C 
and shaken. The reaction mixture was extracted with dichloromethane and analysed via 
HPLC (conditions: 10% IPA / hexane, 1 ml/min at 230 nm). 
 
General procedure for MAO-N D9 / Rc XDH E232V cascades (1 mM) 
 
 
 
To an Eppendorf tube, the substrate in DMF (0.3 µl, 1M), MAO-N D9 (50 µl, 14 
mg/ml), XDH E232V (33 µl, 1 mg/ml) in potassium phosphate buffer (50 mM, pH 7.6), 
potassium ferricyanide (30 µl, 10 mM) or laccase (1.5 U), dichloroindophenol (30 µl, 10 
mM) catalase (100 µl, 3 mg/ml pH 7.6) and potassium phosphate buffer (127 µl, 50 
mM, pH 7.6) were added. The Eppendorf tube was then incubated for the required time 
at 37 °C and shaken. The reaction mixture was extracted with dichloromethane and 
analysed via HPLC on a Diacel OJH column (conditions: 10% IPA / hexane, 1 ml/min 
at 230 nm). 
 
 
MAO-N D9
Ec XDH
Catalase
KPi (50mM p.H 7.6)
191: R1 = H, R2 = H, R3 = H
192: R1 = NO2, R2 = H, R3 = Me
201: R1 = H, R2 = H, R3 = Me
202: R1 = OMe, R2 = OMe, R3 = H
N R3
R1
R2 N R3
R1
R2
O
193: R1 = H, R2 = H, R3 = H
194: R1 = NO2, R2 = H, R3 = Me
203: R1 = H, R2 = H, R3 = Me
204: R1 = OMe, R2 = OMe, R3 = H
192: R1 = NO2, R2 = H, R3 = Me
201: R1 = H, R2 = H, R3 = Me
N R3
R1
R2 N R3
R1
R2
O
194: R1 = NO2, R2 = H, R3 = Me
203: R1 = H, R2 = H, R3 = Me
MAO-N D9
Rc XDH E232V
Catalase
KPi (50mM p.H 7.6)
DCPIP, K3Fe(CN)6 or laccase
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5.3.4. Chemical synthesis  
Synthesis of ethyl (2-phenylethyl)carbamate  
 
 
 
To a solution of phenethylamine (2.5 ml, 20.0 mmol) and triethylamine (3 ml, 22.0 
mmol, 1.1 equiv) in DMF (75 ml), ethyl chloroformate (1.7 ml, 22.0 mmol, 1.1 equiv) 
was slowly added at 0 °C with stirring for 1 hr. Water (250 ml) was added, and the 
whole was extracted with ethyl acetate (3 x 50 ml). The organic phase was washed with 
brine and dried with magnesium sulfate before evaporating the solvent in vacuo. The 
crude oil was purified via column chromatography using 20% ethyl acetate / n-hexane 
to give a clear oil (3.03 g, 85 %). NMR 1H (400 MHz, CDCl3) δ 7.32-7.18 (5 H, m, Ar-
H), 4.71 (1 H, s (br), NH), 4.13-4.07 (2 H, q, J = 7 Hz, CH2), 3.46-3.41 (2 H, t, J = 7 
Hz, CH2), 2.82-2.79 (2 H, t, J = 7 Hz, CH2), 1.24-1.20 (3 H, t, J = 7 Hz, CH3). 13C (100 
MHz, CDCl3) δ 156.6, 138.8, 128.8, 128.6, 126.5 60.7, 42.1, 36.2, 14.6. m/z 194 
([M+H]+, 100). 
 
Synthesis of 3,4-dihydroisoquinolin-1(2H)-one 
 
 
To phenethylcarbamic acid ethyl ester (344 ul, 2.04 mmol), trifluoromethanesulfonic 
acid (9 ml, 101.7 mmol, 50 equiv) was slowly added at 0 °C. The reaction mixture was 
heated to 70 °C with stirring for 24 hr. The whole was then poured into ice water (200 
ml) and extracted with dichloromethane (3 X 100 ml). The organic phase was washed 
with brine and dried over sodium sulfate. Following evaporation of the solvent in vacuo 
the crude residue was purified via column chromatography using 50% ethyl acetate / n-
hexane to give a pale residue (197.5 mg, 64 %). NMR 1H (400 MHz, CDCl3) δ 8.08-
8.06 (1 H, d, J = 8 Hz, Ar-H) 7.47-7.43 (1 H, t, J = 7 Hz, Ar-H), 7.37-7.33 (1 H, t, J = 7 
Hz, Ar-H) 7.23-7.21 (1 H, d, J = 8 Hz, Ar-H), 7.49 (1 H, s, NH), 3.60-3.56 (2 H, td, J = 
N
H
O
O
200
NH
O
193
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7, 3 Hz, CH2), 3.01-2.09 (2 H, t, J = 7 Hz, CH2). 13C (100 MHz, CDCl3) δ 166.6, 138.9, 
132.1, 129.0, 127.9, 127.3, 127.1, 40.2, 28.3. m/z 148 ([M+H]+, 100). 
 
Synthesis of 2-methyl-3,4-dihydroisoquinolinium iodide 
 
 
 
3,4-dihydroisoquinoline (100 mg, 0.76 mmol) was dissolved in acetone (10 ml) and an 
excess of iodomethane (60 ul) was added. The mixture was left to stir overnight at room 
temperature, after which the solvent was evaporated in vacuo to give a yellow solid 
(157 mg, 75 %). NMR 1H (400 MHz, CDCl3) δ 10.03 (1 H, s, CH), 8.05-8.04 (1 H, d, J 
= 8 Hz, aromatic), 7.72-7.68 (1 H, t, J = 8 Hz, Ar-H), 7.47-7.43 (1 H, t, J = 8 Hz, Ar-H), 
7.37-7.35 (1 H, d, J = 8 Hz, Ar-H), 4.14-4.10 (2 H, t, J = 8 Hz, CH2), 4.02 (3 H, s, CH3), 
3.42-3.38 (2 H, t, J = 8 Hz, CH2). 13C (101 MHz, CDCl3) δ 166.6, 138.0, 135.6, 134.4, 
128.6, 128.3, 124.5, 51.0, 48.7, 25.4. m/z 274 ([M+H]+, 30). 
 
Synthesis of 2-methyl-1,2,3,4-tetrahydroisoquinoline 
 
 
 
2-methyl-3,4-dihydroisoquinoline (147.1 mg, 1 mmol) was dissolved in methanol (10 
ml). To this, sodium borohydride (73.5 mg, 2 equivalents) was added and the solution 
was stirred at room temperature for 2 hours after which, the methanol was evaporated in 
vacuo. The resulting residue was extracted with water and diethyl ether, dried over 
magnesium sulfate and evaporated in vacuo to give a yellow oil (56 mg, 38 %). NMR 
1H (400 MHz, CDCl3) δ 7.13-7.09 (3 H, m, Ar-H), 7.02-7.00, (1 H, m, Ar-H), 3.58 (2 
H, s, CH2), 2.94-2.91 (2 H, t, J = 6 Hz, CH2), 2.74-2.67 (2 H, t, J = 6 Hz, CH2), 2.46 (3 
H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 134.7, 133.8, 128.7, 126.4, 126.1, 125.6, 
58.0, 52.9, 46.2, 29.2. m/z 148 ([M+H]+, 100). 
 
 
 
 
N+
I-205
N
201
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Synthesis of 2-methyl-3,4-dihydroisoquinolin-1(2H)-one 
 
 
 
2-methyl-3,4-dihydroisoquinolinium iodide (100 mg, 0.4 mmol) was dissolved in 
DMSO (3.7 ml), to which concentrated hydrochloric acid (0.53 ml) was added. The 
solution was left to stir for an hour at room temperature. 3 M sodium hydroxide (3 ml) 
was added and the solution was worked up with distilled water and diethyl ether before 
being purified by column chromatography (2 % methanol/dichloromethane) to give a 
residue (14.8 mg, 25 %).  NMR 1H (400 MHz, CDCl3) δ 8.09-8.07 (1H, d, J = 8 Hz, Ar-
H), 7.42-7.38 (1H, t, J = 8 Hz, Ar-H), 7.35-7.31 (1H, t, J = 8 Hz, Ar-H), 7.17-7.15 (1H, 
d, J = 8 Hz, Ar-H), 3.58-3.55 (2H, t, J = 7 Hz, CH2), 3.15 (3H, s, CH3) 3.02-2.99 (2H, t, 
J = 7 Hz, CH2). 13C NMR (101 MHz, CDCl3) δ 164.8, 138.0, 131.5, 129.4, 128.1, 
127.0, 126.9, 48.1, 35.2, 27.9. m/z 162 ([M+H]+, 100). 
 
Synthesis of 2-methyl-1,2,3,4-tetrahydroisoquinolin-1-ol 
 
 
 
N-Methyl-tetrahydroisoquinolinium iodide (100 mg, was dissolved in dichloromethane 
(3 ml) and stirred for 15 min and cold NaOH (3 ml, 3 M) was added and left to stir at 
room temperature for 2 hours. The turbid reaction was extracted using dichloromethane 
and water. Following drying over MgSO4, the dichloromethane was removed in vacuo 
to give an oil. (21 mg, 36 %). NMR 1H (400 MHz, CD2Cl2) δ 7.37-7.33 (1H, m, Ar-H), 
7.20-7.16 (2H, m, Ar-H), 7.07-7.04 (1H, m, Ar-H), 4.86 (1H, s, CH), 4.23 (1H, s (br), 
OH), 3.02-2.97 (1H, m, HCH), 2.80-2.77 (2H, t, J = 6 Hz, CH2), 2.61-2.56 (1H, m, 
HCH), 2.36 (3H, s, CH3). 13C NMR (101 MHz, CD2Cl2) δ 138.0, 135.1, 128.6, 128.2, 
128.0, 126.3, 85.5, 46.8, 41.2, 28.8. m/z 130 ([M – H2O + CH3], 100),    
 
 
 
N
203
O
N
OH
206
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Synthesis of N-Me quinolinium iodide  
 
 
 
 
Quinoline (1 g, 0.77 mmol) was dissolved in acetone (50 ml) and an excess of 
iodomethane (2 ml) was added. The mixture was left to stir overnight at room 
temperature, after which the solvent was evaporated in vacuo and the resulting brown 
solid was filtered and washed with cold hexane to give a yellow solid (1.29 g, 61 %). 
NMR 1H (400 MHz, DMSO) δ 9.53-9.51 (1H, dd, J = 6, 1 Hz, Ar-H), 9.30-9.29 (1H, d, 
J = 8 Hz, Ar-H), 8.54-8.52 (1H, dd, J = 9, 1 Hz, Ar-H), 8.51-8.49 (1H, dd, J = 8, 1 Hz, 
Ar-H), 8.32-8.29 (1H, td, J = 8, 2 Hz, Ar-H), 8.20-8.17 (1H, dd, J = 8, 6 Hz, Ar-H), 
8.09-8.06 (1H, td, J = 8, 1 Hz, Ar-H), 4.65 (3H, s, CH3). 13C NMR (101 MHz, DMSO) 
δ 150.7, 147.5, 138.8, 135.9, 130.8, 130.4, 129.7, 122.5, 119.6, 45.9. m/z 258 ([M – 
CH3], 2), 130 ([M – I + CH3]+). 
 
Synthesis of 1-methylquinolin-2(1H)-one  
 
 
1-methyl-quinolinium iodide (100 mg, 0.4 mmol) was dissolved in DMSO (4 ml), to 
which concentrated hydrochloric acid (0.5 ml) was added. The solution was left to stir 
for an hour at room temperature. 3 M sodium hydroxide (3 ml) was added and the 
solution was worked up with distilled water and diethyl ether before being purified by 
column chromatography (2 % methanol/dichloromethane) to give a residue (14.8 mg, 
25 %).  NMR 1H (400 MHz, CDCl3) δ 7.69-7.67 (1H, d, J = 9 Hz, Ar-H), 7.59-7.56 
(2H, m, Ar-H), 7.39-7.37 (1H, dd, J = 8, 1 Hz, Ar-H), 7.26-7.23 (1H, td, J = 8, 1 Hz, 
Ar-H), 6.73-6.71 (1H, d, J = 9 Hz, Ar-H), 3.15 (3H, s, CH3). 13C NMR (101 MHz, 
CDCl3) δ 164.8, 138.0, 131.5, 129.4, 128.1, 127.0, 126.9, 48.1, 35.2, 27.9. m/z 160 
([M+H]+, 100). 
 
N
207
I-
N O
209
Experimental  Chapter 5 | 
 
 111 
Synthesis of dibenzo[b,f][1,4]oxazepine 
 
 
 
2-Fluorobenzaldehyde (105 ul, 1 mmol), 2-aminophenol (120 mg, 1.1 mmol), 
polyethylene glycol (2 ml) and potassium carbonate (138 mg, 1.1 mmol) were added to 
a round bottom flask and heated at 100 °C overnight. After work up with 
dichloromethane and water the crude product was purified via flash column 
chromatography (10 % hexane/ethyl acetate) to give an orange solid (136 mg, 70 %). 
NMR 1H (400 MHz, CDCl3) δ 8.53 (1H, s, NCH), 7.50-7.46 (1H, td, J = 8, 2 Hz, Ar-H), 
7.40-7.37 (2H, td, J = 8, 2 Hz, Ar-H), 7.27-7.19 (3H, m, Ar-H), 7.18-7.15 (2H, td, J = 9, 
2 Hz, Ar-H), 13C NMR (101 MHz, CDCl3) δ 160.6, 160.5, 152.7, 140.5, 133.4, 130.1, 
129.3, 128.8, 127.4, 125.7, 125.1, 121.4, 120.7. m/z 196 ([M+H]+, 100). 
 
Synthesis of dibenzo[b,f]oxazepine lactam 
 
 
 
Dibenzo[b,f][1,4]oxazepine (200 mg, 1 mM) was stirred overnight at room temperature 
in a solution of acetic acid (1.8 ml) and hydrogen peroxide (0.6 ml). The reaction was 
diluted with brine and extracted with chloroform (3 x 25 ml), the extracts were dried 
over sodium sulfate and concentrated before purification via flash column 
chromatography (30% EtOAc/Hexane) to furnish a white solid (21.3 mg, 10%) NMR 
1H (400 MHz, CDCl3) δ 8.48 (1H, s, NH), 7.99-7.97 (1H, dd, 8, 2 Hz, Ar-H), 7.57-7.53 
(1H. td, J = 8, 2 Hz, Ar-H), 7.30-7.28 (3H, m, Ar-H), 7.17-7.15 (2H, m, Ar-H), 7.10-
7.08 (1H, m, Ar-H). 13C NMR (101 MHz, CDCl3) δ 167.6, 159.8, 151.1, 134.6, 132.1, 
130.7, 126.1, 126.0, 125.4, 125.2, 121.8, 121.4, 121.0. m/z 212 ([M+H]+, 100). 
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O
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Syntheisis of 1,4-dihydroquinoxaline-2,3-dione 
 
 
Quinoxaline (65 mg, 0.5 mM) was dissolved in a 3:1 mixture of MeCN/H2O (11 ml and 
4 ml). To this, [Bis(trifluoroacetoxy)iodo]benzene (237 mg, 0.5 mM) was added and the 
reaction was left to stir overnight at room temperature. The reaction mixture was then 
concentrated under vacuum and filtered; washing with water, MeCN and diethyl ether 
to give a brown solid (7 mg, 9 %). NMR 1H (400 MHz, CDCl3) δ 11.91 (2H, s, N-H), 
7.14-7.07 (4H, aromatic, Ar-H). 13C NMR (101 MHz, CDCl3) δ 155.7, 126.1, 123.6, 
115.7. m/z 163 ([M+H]+, 100). 
 
 
5.3.5. NMR UV absorbance calibration 
 
 
 
 
N
H
H
N
O
O
217
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Peak Retention time (min) Area (%) Calibration (x) 
Imine 197 3.02 22.5 1.93 
Amine 201 5.70 43.1 1.00 
Amide 203 9.00 34.3 1.26 
Figure 34 Calibration of HPLC response for ca. 1:1:1 of 197:201:203 (-CH2 triplets)  by  NMR.  
HPLC conditions: Diacel OJ-H column; 1.0 mL/min; UV 230 nm; eluent = hexane/iPrOH 
90:10. 
 
 
Peak Retention time (min)  Corrected Area 
(%) 
Calibration (x) 
Amine 201 5.13 14.0 6.14 
Amide 203 9.43 86.0 1.00 
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Figure 35 Calibration of HPLC response for ca. 1:1 of 196:198 (-NCH3 singlets)  by  NMR.  
HPLC conditions: Diacel OJ-H column; 1.0 mL/min; UV 230 nm; eluent= hexane/iPrOH 90:10. 
  
 
 
 
 
 
 
 
Peak Retention time (min) Area (%) Calibration (x) 
Hydroxyl 206 8.09 62.2 1.00 
Amide 203 9.20 37.8 1.65 
Figure 36 Calibration of HPLC response for ca. 1:1 of 201:198 (-NCH3 singlets)  by  NMR.  
HPLC conditions: Diacel OJ-H column; 1.0 mL/min; UV 230 nm; eluent= hexane/iPrOH 90:10. 
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Peak Retention time (min) Corrected Area 
(%) 
Calibration (x) 
Amine 237 5.3 28.2 2.55 
Amide 209 11.9 71.8 1.00 
Figure 37 Calibration of HPLC response for ca. 1:1 of 237:209 (-NCH3 singlets)  by  NMR.  
HPLC conditions: Diacel OJ-H column; 1.0 mL/min; UV 230 nm; eluent= hexane/iPrOH 90:10. 
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Peak Retention time (min) CorrectedArea 
(%) 
Calibration (x) 
Imine 203 12.2 51.7 1.00 
Amide 208 9.7 48.3 1.07 
Figure 38 Calibration of HPLC response for ca. 1:1 of 203:208 (-CH singlet)  by  NMR.  HPLC 
conditions: Diacel OJ-H column; 1.0 mL/min; UV 230 nm; eluent= hexane/iPrOH 90:10. 
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5.3.6. Bicyclic imine screen with XORs  
 
 
 
To an Eppendorf tube, the substrate in DMF (10 µl, 1 M), XOR (100 µl, 1 mg/ml) in 
potassium phosphate buffer (100 mM, pH 8), catalase (100 µl, 3 mg/ml pH 8) and 
potassium phosphate buffer (798 µl, 100 mM, pH 8) were added. In the case of Rc XDH 
E232V potassium phosphate buffer (598 µl, 100 mM, pH 8), potassium ferricyanide 
(100 µl, 10 mM), DCPIP (100 µl, 10 mM). The Eppendorf tube was then incubated for 
the required time at 37 °C and shaken. The reaction mixture was centrifuged, filtred and 
analysed via RP-HPLC (215) Thermo Fischer Scientific C-18 column, 70:30 deionised 
water (containing 0.1 % trifluoroacetic acid): Acetonitrile UV 254 nm. NMR in DMSO-
d6 compared 211, 218 and 219 with authentic standards (Appendix).  
 
5.4. Chapter 3 Experimental 
 
5.4.1. Libraries 
 
Libraries were made by designing primers at the selected regions of the Moco 
containing PaoC subunit (residue 184 - 458) and following the protocol from the 
“GeneMorph II EZclone Domain Mutagenesis Kit” (Agilent Technolgies).  
 
5.4.1.1. Mutant megaprimer synthesis 
 
Forward primer = 5’-GCG GTG AAG ATT GAT GCT AC-3’.  
Reverse primer = 5’-CCA ATG TCG GTC ATG TCC G-3’.  
 
The PCR reaction was made up of the following: 10x Mutazyme II reaction buffer (5 
µl), PaoABC template plasmid (4.4 µl, 235 ng/µl), forward primer (1 µl, 125 ng/µl), 
reverse primer (1 µl, 125 ng/µl), dNTP mix (1 µl, 40 mM), Mutazyme II DNA 
polymerase (1 µl, 2.5 U/µl) and dH2O (37.6 µl). The following thermal cycle program 
was used. 
 
N
N
215
NH
N
N N
N
O218 219211
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Table 19 Megaprimer PCR program 
Segment Number of cycles Temperature (° C) Duration 
1 30 95 30 sec 
  55 30 sec 
  72 1 min 
2 1 72 10 min 
 
The megaprimer was isolated through agarose gel electrophoresis and purified by 
excising the band and using a DNA purification kit from Agilent. 
 
 
Figure 39 Agarose gel containing megaprimer band 
 
5.4.1.2. Mega primer cloning reaction 
 
The PCR reaction was made up of the following: 2x EZClone enzyme mix (25 µl), 
PaoABC template plasmid (2.1 µl, 23.5 ng/µl), megaprimer (22 µl, 11.36 ng/µl) and 
EZClone solution (3 µl). The following thermal cycle program was used. 
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Table 20 cloning PCR program 
Segment Number of cycles Temperature (° C) Duration 
1 1 95 1 min 
2 25 95 50 sec 
  60 50 sec 
  78 17 min 
 
DPN I restriction enzyme (1 µl) was added to PCR products and incubated at 37 °C for 
2 h following mixing and centrifugation (1 min, 5000 RPM). The mixture (1.5 µl) was 
added to an aliquot (45 µl) of thawed XL10-Gold ultra competent cells. The cells were 
left on ice for 30 min and heat-pulsed (42 °C 30 seconds). Transformed cells were 
incubated in NZY+ broth for an hour prior to plating on Highbond-N membranes. 
 
5.4.2. Solid phase screen 
 
The solid phase screen was used both to screen libraries and to confirm isolated mutants 
for activity. E. coli TP1000 (ΔmobAB) was transformed with either a library, the 
wildtype or a single/double mutant. The transformation reaction was plated on a 
membrane (HyBond-N) on LB containing 100 µg / mL ampicillin, 1 mM IPTG and 
grown / induced overnight at 37 °C after which membranes were kept frozen at -20 °C 
until use. Membranes were freeze-thawed three times (using liquid N2) before being 
placed on filter paper containing 0.14 mg / mL Horse-radish peroxidase (HRP) (Sigma) 
in pH 8.0, 0.1 M potassium phosphate buffer. The membranes were left at room 
temperature for 1 hour. This ensured removal of any cellular H2O2. The membrane was 
the transferred to another filter paper containing a solution of 0.1 mg / mL HRP, 3,3'-
Diaminobenzidine (DAB) (1 tablet per 15 mL, SigmaFast, Sigma) or 4-chloronapthol 
(4-CN) 16.8 mM, and 1-20 mM substrate. Colonies which turned dark red (DAB) / dark 
blue (4-CN) indicated oxidation of the substrate. For screening a panel of conditions, 
the membrane was cut into smaller pieces and each piece placed on a filter paper.  
 
5.4.3 Synthesis of acyclic imines 
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5.4.3.1 Synthesis of 2-[(E)-(benzylimino)methyl]phenol 
 
 
 
Salicaldehyde (4.3 ml, 40.1 mM) and benzylamine (3.7 ml, 40.1 mM) were added to 
DCM (20 ml) and molecular sieves. Stirring overnight followed by filtration and 
removal of solvent afforded a white solid (2.66 g, 31 %) NMR 1H (500 MHz, CD2Cl2) δ 
14.30 (1H, s, OH) 8.47 (1H, s, HC=N) 7.38-7.27 (7H, m, Ar-H), 6.92-6.88 (2H, m, Ar-
H), 4.80 (2H, s CH2). 13C NMR (101 MHz, CDCl3) δ 165.7, 161.2, 138.3, 132.5, 131.5, 
132.5, 128.8, 127.9, 127.5, 119.0, 118.7, 117.2, 63.3. m/z 212 ([M+H]+, 100). 
 
5.4.3.2. Synthesis of N-[(E)-(4-methoxyphenyl)methylidene]-1-phenylmethanamine 
 
 
 
4-methoxybenzaldehyde (4.5 ml, 36.6 mmol) and benzylamine (3.8 ml, 36.6 mM) were 
added to DCM (20 ml) and molecular sieves. Stirring overnight followed by filtration 
and removal of solvent afforded a white solid (0.68 g, 8 %) NMR 1H (500 MHz, 
CD2Cl2) δ 8.33 (1H, s, HC=N), 7.72-7.70 (2H, d, J= 8 Hz, Ar-H), 7.37-7.36 (4H, m, Ar-
H), 7.30-7.27 (1H, m, Ar-H), 6.96-6.92 (2H, d, J = 8 Hz, Ar-H), 4.74 (2H, s, N-CH2), 
3.83 (3H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 139.6, 129.9, 129.2, 128.5, 127.9, 
126.9, 114.0, 65.0, 55.4. m/z 226 ([M+H]+, 100). 
 
5.4.3.3. Synthesis of (1E)-N-methoxy-2-phenylethanimine 
 
 
 
Phenylacetaldehyde (0.48 ml, 4 mM), methoxyamine hydrochloride (0.35 mg, 4 mM) 
N
OH
234
N
O
235
N O
236
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and triethylamine (0.58 ml, 4 mM) were added to DCM (20 ml) and molecular sieves. 
Stirring overnight followed by filtration and removal of solvent afforded a white solid 
(142 mg, 25 %). NMR 1H (500 MHz, CD2Cl2) Rotamers E/Z 55/45 δ 7.45-7.43 (1H, t, J 
= 7 Hz, C-H), 7.32-7.29 (4H, m, Ar-H), 7.25-7.20 (6H, m, Ar-H), 6.78-6.76 (1H, t, J = 
6 Hz, C-H), 3.94 (3H, s, CH3), 3.86 (3H, s, CH3), 3.67 (2H, d, J = 6 Hz, CH2), 3.52 (2H, 
d, J = 7 Hz, CH2). 13C NMR (101 MHz, CDCl3) δ 149.7, 149.2, 136.9, 136.4, 128.8, 
126.9, 126.6, 61.8, 61.4, 35.9, 32.3. m/z 150 ([M+H]+, 100). 
 
 
5.4.4. Acyclic 224 imine transformation with Ec PaoABC 
 
 
 
To an Eppendorf tube, 234 in DMF (3 µl, 1 M), PaoABC (33 µl, 3 mg/ml) in potassium 
phosphate buffer (100 mM, pH 8), catalase (100 µl, 3 mg/ml pH 8) and potassium 
phosphate buffer (164 µl, 100 mM, pH 8) were added. The Eppendorf tube was then 
incubated for 5 h at 37 °C and shaken. The reaction mixture was centrifuged, filtred and 
analysed via RP-HPLC conditions: Thermo Fischer Scientific C-18 column, 70:30 
deionised water (containing 0.1 % trifluoroacetic acid): Acetonitrile UV 254 nm.  
 
 
Figure 40  RP-HPLC of 224 and PaoABC 
 
5.5. Chapter 4 Experimental 
 
5.5.1. Site directed mutagenesis 
 
Site directed mutations were made by designing primers with the required mutations at 
the appropriate regions following instructions from the “QuickChange II Site-Directed 
Mutagenesis Kit” (Agilent Technologies).  
N
OH
234
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L246E  
Forward primer = 5'-GAG GGT TTG GCG GCA AGG AAT TCC TGA GAA GCG 
ATG C-3'  
Reverse primer = 5'-GCA TCG CTT CTC AGG AAT TCC TTG CCG CCA AAC CCT 
C-3'.  
 
T318R  
Forward primer = 5'-CCT GCC CGG CGG CAC GCC GGA AAG GGC GGT ACA 
GC-3' 
Reverse Primer = 5'-GCT GTA CCG CCC TTT CCG GCG TGC CGC CGG GCA GG-
3' 
 
The PCR reactions for L246E and T318R were made up of the following: 10x reaction 
buffer (5 µl), PaoABC template plasmid (2 µl, 25 ng/µl), forward primer (1 µl, 125 
ng/µl), reverse primer (1 µl, 125 ng/µl), dNTP mix (1 µl), PfuUltra HF DNA 
polymerase (1 µl, 2.5 U/µl), DMSO (3 µl) and dH2O (36 µl). The following thermal 
cycle program was used. 
 
Table 21 Site-directed mutagenesis PCR program 
Segment Number of cycles Temperature (° C) Duration 
1 1 95 30 sec 
2 25 95 30 sec 
  55 1 min 
  68 8.6 min 
 
The double mutant was produced by substituting the WT template for purified L246E 
plasmid using T318R primers. 
 
DPN I restriction enzyme (1 µl) was added to PCR products and incubated at 37 °C for 
2 h following mixing and centrifugation (1 min, 5000 RPM). The mixture (1.5 µl) was 
added to an aliquot (45 µl) of thawed XL10-Gold ultra competent cells. The cells were 
left on ice for 30 min and heat-pulsed (42 °C 30 seconds). Transformed cells were 
incubated in NZY+ broth for an hour prior to plating on Highbond-N membranes. 
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5.5.2. Saturation mutagenesis 
 
Site saturation libraries were produced by designing primers with degenerate codons at 
the L246 and T318 positions of the Moco containing PaoC subunit and following the 
protocol from the “QuickChange II Multi Site-Directed Mutagenesis Kit” (Agilent 
Technolgies). 
 
L246 
Forward primer = 5’-GTT TGG CGG CAA GNN KTT CCT GAG AAG CGA TGC 
CCT GCT GGC GGC C-3’ 
Reverse primer = 5’-CTT CTC AGG AAM NNC TTG CCG CCA AAC CCT CCG 
CCG ATA TAC GG-3’ 
 
T318 
 
Forward primer = 5’-CCC GGC GGC ACG CCG GAA NNK GCG GTA CAG 
CAA AG-3’ 
Reverse primer = 5’-CTT TGC TGT ACC GCM NNT TCC GGC GTG CCGCCG GG-
3’ 
 
The PCR reactions for L246 and T318 saturation mutagenesis were made up of the 
following: 10x QuickChange multi reaction buffer (10 µl), PaoABC template plasmid 
(1 µl, 325 ng/µl), QuickSolution (0.5 µl) forward primer (1 µl, 125 ng/µl), reverse 
primer (1 µl, 125 ng/µl), dNTP mix (1 µl), QuickChange multi enzyme blend (1 µl) and 
DMSO (5 µl) dH2O (79 µl). The following thermal cycle program was used. 
 
Table 22 Saturation mutagenesis PCR program 
Segment Number of cycles Temperature (° C) Duration 
1 1 95 1 min 
2 30 95 1 min 
  55 1 min 
  65 17.2 min 
 
DPN I restriction enzyme (2 µl) was added to PCR products and incubated at 37 °C for 
3 h following mixing and centrifugation (1 min, 5000 RPM). The mixture (1.5 µl) was 
added to an aliquot (45 µl) of thawed XL10-Gold ultra competent cells. The cells were 
left on ice for 30 min and heat-pulsed (42 °C 30 seconds). Transformed cells were 
incubated in NZY+ broth for an hour prior to plating on Highbond-N membrane.
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Figure 41 Aromatic region NMR standards 211 and 212 and Ec XDH in DMSO-d6 
 
 
 
Figure 42 Ec XDH quinoline 211 : 2-hydroxyquinoline 212 = 1:1.15 
 
 
Figure 43 Rc XDH E232V quinoline 211 : 2-hydroxyquinoline 212 = 1:1.5  
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Figure 44 Aromatic region NMR standards of 218, 219, 220, in DMSO-d6 
 
 
Figure 45 PaoABC 218 trace in DMSO-d6 
 
 
Figure 46 EcXDH / Bovine XO 218 trace in DMSO-d6 
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Figure 47 Ec PaoABC T318R quinazoline 218 : 219 = 1:1.34 
 
 
 
Figure 48 Rc XDH E232V quinazoline 218 : 219 = 1:1471 
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Phenylacetaldehyde – WT PaoABC 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 1.1515 x 136.36 = 157.0 min-1 (± 11.0)  
 
kcat/Km = 2916 (± 627) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 1.15 8.10x10-2 0.98 to 1.32 
Km 5.39x10-2 1.10x10-2 3.12x10-2 to 7.65x10-2 
 
 
 
 
 
 
 
Michaelis-Menten
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Phenylacetaldehyde – PaoABC L443Q 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 1.3013 x 136.36 = 177.4 min-1 (± 6.5)  
 
kcat/Km = 4080 (± 474) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 1.30 4.80x10-2 1.20 to 1.40 
Km 4.34x10-2 4.80x10-3 3.34x10-2 to 5.34.x10-2 
 
 
 
 
 
 
 
Michaelis-Menten
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Phenylacetaldehyde – PaoABC L246E 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.8023 x 136.36 = 109.4 min-1 (± 11.9)  
 
kcat/Km = 33 (± 6) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.80 8.76x10-2 0.62 to 0.98 
Km 3.29 0.52 2.23 to 4.34 
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Phenylacetaldehyde – PaoABC T318R 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.2235 x 136.36 = 30.5 min-1 (± 0.7)  
 
kcat/Km = 3020 (± 672) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.22 5.40x10-3 0.21 to 0.24 
Km 1.01x10-2 2.30x10-3 5.38x10-3 to 1.49x10-2 
 
 
 
 
 
 
 
Michaelis-Menten
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Phenylacetaldehyde – PaoABC L246E/T318R 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.6621 x 136.36 = 90.3 min-1 (± 7.1)  
 
kcat/Km = 37 (± 5) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.66 5.20x10-2 0.55 to 0.77 
Km 2.45 0.30 1.82 to 3.08 
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Phenylacetaldehyde – PaoABC L246G 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.0481 x 136.36 = 6.6 min-1 (± 0.3)  
 
kcat/Km = 114 (± 19) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 4.81x10-2 2.10x10-3 4.40x10-2 to 5.20x10-2 
Km 5.81x10-2 9.60x10-3 3.84x10-2 to 7.77x10-2 
 
 
 
 
 
 
 
Michaelis-Menten
[Substrate] (mM)
0.0 0.5 1.0 1.5 2.0 2.5
R
at
e 
(µ
m
ol
/m
in
/m
g)
0.00
0.01
0.02
0.03
0.04
0.05
 Vmax = 0.04815
 Km = 0.05806
  Appendix 
 
 140 
Phenylacetaldehyde – PaoABC L246V 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 1.004 x 136.36 = 136.9 min-1 (± 36.8)  
 
kcat/Km = 27 (± 12) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 1.00 0.27 0.44 to 1.56 
Km 5.11 1.81 1.40 to 8.81 
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Phenylacetaldehyde – PaoABC L246S 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.663 x 136.36 = 90.4 min-1 (± 15.0)  
 
kcat/Km = 29 (± 8) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.66 0.11 0.44 to 0.89 
Km 3.15 0.75 1.62 to 4.68 
 
 
 
 
 
 
 
Michaelis-Menten
[Substrate] (mM)
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Phenylacetaldehyde – PaoABC T318G 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.199 x 136.36 = 27.1 min-1 (± 0.4)  
 
kcat/Km = 932 (± 78) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.20 2.82x10-3 0.19 to 0.20 
Km 2.91x10-2 2.39x10-3 2.42x10-2 to 3.41x10-2 
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Phenylacetaldehyde – PaoABC T318P 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.173 x 136.36 = 23.6 min-1 (± 0.4)  
 
kcat/Km = 900 (± 85) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.17 2.63x10-3 0.17 to 0.18 
Km 2.62x10-2 2.43x10-3 2.12x10-2 to 3.13x10-2 
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Phenylacetaldehyde – PaoABC T318L 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.111 x 136.36 = 15.1 min-1 (± 0.8)  
 
kcat/Km = 610 (± 183) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.11 6.05x10-3 9.89x10-2 to 0.12 
Km 2.48x10-2 7.30x10-3 2.12x10-2 to 3.13x10-2 
 
 
 
 
 
 
 
Michaelis-Menten
[Substrate] (mM)
0.0 0.5 1.0 1.5 2.0 2.5
R
at
e 
(µ
m
ol
/m
in
/m
g)
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
 Vmax = 0.1113
 Km = 0.02476
  Appendix 
 
 145 
Phenylacetaldehyde – PaoABC T318E 
 
 
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.111 x 136.36 = 15.1 min-1 (± 0.3)  
 
kcat/Km = 610 (± 183) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.19 2.22x10-3 0.18 to 0.19 
Km 2.48x10-2 7.30x10-3 1.57x10-2 to 2.16x10-2 
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Phenylacetaldehyde – PaoABC T318S 
 
Michaelis-Menten
[Substrate] (mM)
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 Vmax = 0.1446
 Km = 0.01798  
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.145 x 136.36 = 19.8 min-1 (± 0.3)  
 
kcat/Km = 1098 (± 429) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 0.14 8.72x10-3 0.13 to 0.16 
Km 1.80x10-2 6.94x10-3 3.76x10-3 to 3.22x10-2 
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Dihydroisoquinoline – EcXDH 
 
Michaelis-Menten
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Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.0549 x 136.36 = 7.49 min-1 (± 0.42)  
 
kcat/Km = 2.34 (± 0.33) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 5.49x10-2 3.09x10-3 4.80x10-2 to 6.12x10-2 
Km 3.20 0.41 2.32 to 4.02 
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Dihydroisoquinoline – WT PaoABC 
 
Michaelis-Menten
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Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.0009067 x 136.36 = 0.12 min-1 (± 7.31x10-3)  
 
kcat/Km = 0.08 (± 0.01) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 9.07x10-4 5.36x10-5 7.96x10-4 to 1.02x10-3 
Km 1.55 0.26 1.02 to 2.08 
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Dihydroisoquinoline – PaoABC L246G 
 
Michaelis-Menten
[Substrate] (mM)
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Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.003939 x 136.36 = 0.54 min-1 (± 3.94x10-2)  
 
kcat/Km = 2.24 (± 0.47) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 3.90x10-3 2.89x10-4 3.33x10-3 to 4.55x10-3 
Km 0.24 4.72x10-2 0.14 to 0.34 
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Dihydroisoquinoline – PaoABC L246S 
 
Michaelis-Menten
[Substrate] (mM)
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 Km = 0.224  
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.001797 x 136.36 = 0.25 min-1 (± 1.16x10-2)  
 
kcat/Km = 1.11 (± 0.18) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 1.80x10-3 8.49x10-5 1.62x10-3 to 1.97x10-3 
Km 0.22 3.41x10-2 0.15 to 0.29 
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Dihydroisoquinoline – PaoABC T318G 
 
Michaelis-Menten
[Substrate] (mM)
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Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.0006937 x 136.36 = 0.09 min-1 (± 5.33x10-3)  
 
kcat/Km = 0.04 (± 6.51x10-3) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 6.94x10-4 3.91x10-5 6.13x10-4 to 7.75x10-4 
Km 2.33 0.35 1.61 to 3.06 
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Dihydroisoquinoline – PaoABC T318P 
 
Michaelis-Menten
[Substrate] (mM)
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Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.0009875 x 136.36 = 0.13 min-1 (± 2.00x10-2)  
 
kcat/Km = 0.04 (± 0.01) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 9.88x10-4 1.46x10-4 6.83x10-4 to 1.29x10-3 
Km 3.69 1.20 1.18 to 6.20 
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Dihydroisoquinoline – PaoABC T318E 
 
Michaelis-Menten
[Substrate] (mM)
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Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.0009809 x 136.36 = 0.13 min-1 (± 2.43x10-2)  
 
kcat/Km = 0.05 (± 0.01) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 9.81x10-4 1.78x10-4 6.03x10-4 to 1.36x10-3 
Km 2.65 0.93 0.69 to 4.62 
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Dihydroisoquinoline – PaoABC T318S 
 
Michaelis-Menten
[Substrate] (mM)
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 Km = 4.1  
 
Calculation 
 
Pao MW = 136357.7 g mol-1 (mg mmol-1) = 136.36 mg umol-1  
 
Vmax unit = umol min-1 mg-1 Km unit = mM 
 
kcat = 0.0009895 x 136.36 = 0.13 min-1 (± 8.82x10-2)  
 
kcat/Km = 0.03 (± 5.00x10-3) min-1 mM-1 
 
Parameters 
 Value ±Std. Error 95% Conf. Interval 
Vmax 9.90x10-4 6.47x10-4 8.54x10-4 to 1.13x10-3 
Km 4.10 0.57 2.91 to 5.28 
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